CN1459459A - Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk - Google Patents

Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk Download PDF

Info

Publication number
CN1459459A
CN1459459A CN03141007A CN03141007A CN1459459A CN 1459459 A CN1459459 A CN 1459459A CN 03141007 A CN03141007 A CN 03141007A CN 03141007 A CN03141007 A CN 03141007A CN 1459459 A CN1459459 A CN 1459459A
Authority
CN
China
Prior art keywords
extract
dextran
cell
mouse
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN03141007A
Other languages
Chinese (zh)
Other versions
CN100471869C (en
Inventor
周喜林
朱家荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinese University of Hong Kong CUHK
Original Assignee
Chinese University of Hong Kong CUHK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinese University of Hong Kong CUHK filed Critical Chinese University of Hong Kong CUHK
Publication of CN1459459A publication Critical patent/CN1459459A/en
Application granted granted Critical
Publication of CN100471869C publication Critical patent/CN100471869C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composite and its method for stimulating immune system are disclosed. Such a method includes extracting from polystictus and purifying peptidoglucan or its active components. The said method can be used for preventing and curing the secondary immune deficiency.

Description

Preparation and calibrating have the immunoregulatory peptide connection dextran of verifiable oral absorption rainbow conk
With reference to related application
The application is the non-provisional application of the U. S. application submitted on May 22nd, 2002 number 60/383,339, is hereby incorporated by reference in full with it.The statement of the rights and interests of the invention that the research of relevant federal funding or exploitation are carried out down
Inapplicable reference " sequence table ", form or the computer program table appendix of submitting to mini disk
Be suitable for
Background of invention
When isolating defective had caused clinical disease, indivedual immunologic function compositions had been illustrated very clearly to the importance of host's natural defence.Because so can effectively detect by new laboratory method and limit unusual now, immune deficiency disorder is found at faster speed.The immune deficiency disorder must be considered in two big classes: elementary immune deficiency, and often by heredity decision and secondary immune deficiency state.The latter as infect and infect, the complication of stomach disorder, nutritional trouble, aging, lymph malignant tumour, other cancers and many other diseases takes place.The immune deficiency that severity is different also runs into the side effect that many treatment patterns comprise the radiation and chemotherapy of cancer.From then on viewpoint, the primary and secondary immune deficiency is not rare disease.These problems must be studied the new therapeutic agent with immunologic facilitation characteristic.
Finding in the pathogenesis of the disease that number increases gradually has immune participation, has caused people to attempt to regulate by the various factors of handling immunologic mechanism the process of these diseases inevitably.Stimulating immune system usually is the selection that relaxes immune deficiency state.This approach, the potent agent (being genus bacillus Calmette-Guerin, intracellular toxin) that wherein has several covers nowadays can get, two main treatment fields in medicine---cancer has special prospect with catching.
According to the notion of immunological surveillance, when malignant cell occurred, immunity system was just eliminated them.T cell and nearer scavenger cell, the antitumous effect of natural killer cell have had report.In addition, even anti-tumor immune response does not mainly relate to the control of tumor growth, seeming suitable immunostimulation can cause efficient immune or give originally invalid reaction with effecting reaction.All these Considerations provide basis for immunostimulation as the householder method of surgical operation, radiotherapy or chemotherapy in treatment for cancer 1
In the catching of animal model, immunostimulant is broad research also.Infected individuals presents the immune deficiency problem that is identified and often shows the chance infection by microorganisms, should benefit from immunotherapy in theory.But should be noted that, with immune deficiency not the infection of significant correlation also can treat with immunostimulant can help to eliminate the special strong toxic agent that checks normal physiological reaction because booster immunization is replied.In addition, old and feeble individual situation should give special concern, and they often lack reaction (for example influenza vaccines) to many vaccines.
Brief description of the present invention
In one aspect, the invention provides the extract of the purifying of rainbow conk (coriolus versicolor), it comprises at least a peptide connection dextran that contains the dextran molecule that connects by (1 → 3) key, has the 0.7kDa that determined by the size exclusion chromatography molecular weight to 5kDa; With immunostimulatory activity is provided.On the other hand, the invention provides the isolating peptide connection dextran of rainbow conk, it comprises the dextran molecule that a plurality of (1 → 3) key connects, and has the 0.7kDa that determined by the size exclusion chromatography molecular weight to 3.0kDa; And isolating peptide joins dextran and activeconstituents has immunostimulatory activity.The present invention further provides the pharmaceutical composition that the isolating peptide that comprises rainbow conk joins dextran and activeconstituents thereof.
On the other hand, the invention provides from the method for rainbow conk purified peptide connection dextran, it comprises the following steps: to use alkaline purification rainbow conk, separation of supernatant; Supernatant liquor is carried out cationic exchange, will carry out cationic exchange from the eluate of cationic exchange; To separate by the size fractionation isolation technique from the eluate of anionresin, and recovery comprises peptide connection dextran, molecular weight is the component of 0.7kDa to 5kDa.
On the other hand, the invention provides the method that immune stimulatory is replied, it comprises immune cell and extract, peptide connection dextran or its activeconstituents is contacted.On the other hand, the invention provides the method that treatment needs the patient of immunity system stimulation, comprise that peptide connection dextran or its activeconstituents to the described extract of the claim of patient's effective dosage, purifying comes immune stimulatory to reply.
Brief description of drawings
Figure l is that explanation CV slightly gets the schema of used step in the preparation scheme of thing.
Fig. 2 A and 2B.Fig. 2 A is the size exclusion chromatography spectrum, and it shows the elution profile of the protein component of CV crude extract.Fig. 2 B is the size exclusion chromatography spectrum of CV crude extract, and it shows the elution profile of the carbohydrate components of CV crude extract.
Fig. 3 illustrates the propagation with CV crude extract or the external mice spleen cell alive that contacts of concanavalin A (Con A).
Fig. 4 illustrates the cultivation effect with CV crude extract or the external isolating mouse medullary cell that contacts of LPS.
Fig. 5 explanation increases with CV crude extract or the external mouse peritoneal macrophages secretion nitrogen protoxide that contacts of LPS.
Fig. 6 A and 6B.Fig. 6 A illustrates with effect in the body of the splenocyte alive of the mouse of CV crude extract intraperitoneal (i.p.) administration processing (plan of taking medicine in 3 days).The vitro proliferation effect of the medullary cell alive of (plan of taking medicine in 3 days) is handled in Fig. 6 B explanation with the administration of CV crude extract intraperitoneal.
Fig. 7 A and 7B.Fig. 7 A illustrates with effect in the body of the splenocyte alive of the normal mouse of CV crude extract oral administration treatment (plan of taking medicine in 7 days).Fig. 7 B illustrates the vitro proliferation effect with the medullary cell alive of the normal mouse of CV crude extract oral administration processing (plan of taking medicine in 7 days).
Fig. 8 A, 8B and 8C.Fig. 8 A illustrates with effect in the body of the splenocyte alive of the mouse of the non-responsiveness of CV crude extract intraperitoneal administration processing (plan of taking medicine in 3 days) and the medullary cell of living.Fig. 8 B illustrates with effect in the body of the splenocyte alive of the mouse of the non-responsiveness of CV crude extract oral administration processing (plan of taking medicine in 7 days) and the medullary cell of living.Fig. 8 C illustrates with effect in the body of the splenocyte alive of the mouse of the severe non-responsiveness of CV crude extract oral administration processing (plan of taking medicine in 7 days) and the medullary cell of living.
Fig. 9 A, 9B and 9C.Fig. 9 A illustrates with effect in the body of splenocyte alive of the mouse of the severe non-responsiveness of CV crude extract oral administration processing (plan of taking medicine in 14 days) and medullary cell.Fig. 9 B illustrates the vitro proliferation effect with the splenocyte alive of the mouse of the severe non-responsiveness of CV crude extract oral administration processing (plan of taking medicine in 14 days).Fig. 9 C illustrates the vitro proliferation effect with the medullary cell alive of the mouse of the severe non-responsiveness of CV crude extract oral administration processing (plan of taking medicine in 14 days).
Figure 10 illustrates with effect in the body of splenocyte alive of the mouse of the non-responsiveness of the CV crude extract oral administration processing (plan of taking medicine in 7 days) of various dosage and medullary cell.
Figure 11 illustrates with CV crude extract oral administration and handles, and uses 2 then, and that 4-dinitrobenzene-1-fluorobenzene (DNFB) is attacked is normal, the ear of immunosuppression and serious immunosuppressant mouse is measured.
Figure 12 A, 12B and 12C.Figure 12 A illustrates with effect in the body of the splenocyte alive of the normal mouse of CV crude extract oral administration processing (plan of taking medicine in 30 days) and medullary cell.Figure 12 B illustrates the vitro proliferation effect with the splenocyte alive of the normal mouse of CV crude extract oral administration processing (plan of taking medicine in 30 days).Figure 12 C illustrates the vitro proliferation effect with the medullary cell alive of the normal mouse of CV crude extract oral administration processing (plan of taking medicine in 30 days).
Figure 13 illustrates the propagation with thick CV extract, CV-D2, CV-D3, CV-D4 and the external mice spleen cell alive that contacts of CV-5.
Figure 14 illustrates that the mouse peritoneal macrophages secretion nitrogen protoxide with CV crude extract, CV-E8, CV-E6, CV-E4, CV-E2, the external contact of CV-E0 increases.
Figure 15 is a schema, illustrates at the thick CV extract from Fig. 1 to be further purified step used the scheme of activeconstituents.
Figure 16 illustrates the composition of CV component basic structural unit (neutral sugar, uronic acid and proteins/peptides) and the relation of external mitogenic activity.
Figure 17 shows 3 partially purified CV active parts, and promptly C1D5E8, C1D5E7 and C1D5EX secrete nitric oxide production stimulated in vitro activity to the mouse peritoneal macrophages.
Figure 18 A and 18B.Figure 18 A is the chromatogram of the molecular weight distribution of explanation CV crude extract.Figure 18 B is the chromatogram of explanation through the molecular weight distribution of the CV crude extract composition of Caco-2 cell monolayer.
Figure 19 A and 19B.Figure 19 A is the chromatogram of the molecular weight distribution of the partially purified extract C 1D5E8 of explanation CV.Figure 19 B is the chromatogram of explanation through the molecular weight distribution of the C1D5E8 extract component of Caco-2 cell monolayer.
Figure 20 A and 20B.Figure 20 A is the chromatogram of the molecular weight distribution of explanation CV partial purification extract C 1D5E7.Figure 20 B is the chromatogram of explanation through the molecular weight distribution of the C1D5E7 extract component of Caco-2 cell monolayer.
Figure 21 A and Figure 21 B.Figure 21 A is the chromatogram of the molecular weight distribution of explanation CV partial purification extract C 1D5EX.Figure 21 B is the chromatogram of explanation through the molecular weight distribution of the C1D5EX extract component of Caco-2 cell monolayer.
Figure 22 explanation is secreted nitric oxide production external influence with the composition of the permeable Caco-2 cell monolayer of the partially purified extract of CV or the mouse peritoneum scavenger cell that LPS contacts.
Figure 23 A and 23B.Figure 23 A explanation is with influencing in the body of the splenocyte alive of the mouse of the non-responsiveness of the partially purified extract intraperitoneal of CV administration processing (plan of taking medicine in 3 days).Figure 23 B explanation is with influencing in the body of the medullary cell alive of the non-responsiveness mouse of the partially purified extract intraperitoneal of CV administration processing (plan of taking medicine in 3 days).
Figure 24 A and 24B.Figure 24 A explanation is with influencing in the body of the splenocyte alive of the non-responsiveness mouse of the partially purified extract oral administration processing of CV (plan of taking medicine in 7 days).Figure 24 B explanation is with influencing in the body of the medullary cell alive of the non-responsiveness mouse of the partially purified extract oral administration of CV (plan of taking medicine in 7 days).
Detailed description I. definition of the present invention
For the purposes of the present invention, as the term below having given a definition:
" immunostimulant ", " immunostimulation reagent " and " immunomodulator ", as used herein, refer to the reagent of induce immune response.
" immunogen " refers to cause immunne response or immunogenic reagent or material.
" immunogenicity " refers to the ability of immunogen induce immune response.
" immune deficiency " refers to any defective in the immunne response ability, as the defective production of body fluid or cell-mediated immunity.
" immunocompetence " refers to antigen or immunogenic immunne response ability.
" non-specific immunity " refer to by antibody form and the generation of specific antigen responder cell beyond the resistance that any other mechanism produced to the pathogenic agent invasion.
" peptide " refers to comprise any material of the amino-acid residue that connects by amido linkage.
" polysaccharide " refers to a class carbohydrate, and wherein this molecule is from the polymerization of monose subunit.Polysaccharide contains 5 or more a plurality of by the interconnective monose subunit of glycosidic link usually.
" dextran " refers to the polysaccharide be made up of glucose.
Term " immune-mediated " refers to the natural autoimmunization or the process of inflammatory.
The activeconstituents of extract or composition is a kind of composition of stimulating immune system.
Term " white corpuscle " refers to white cell.Lymphocyte, monocyte and scavenger cell are leukocytic examples.
Term " lymphocyte " refers to mediate the monocyte of body fluid or cellular immunity.
Term " monocyte " refers to become in migrating to tissue before the scavenger cell, temporary transient round-robin mononuclear macrophage white corpuscle in blood flow.
" T cell " refers to maturation and the lymphocyte of expressing TXi Baoshouti, CD3 and CD4 or CD8 in thymus gland.There are several T cell subsets that are identified.
" patient " comprises people and other mammalian subjects of accepting prevention or therapeutic treatment.
Term " isolating ", " purifying " or " pure substantially " refer to enrichment or isolating target variety from the composition of its natural surroundings.So the peptide connection dextran in extract is isolating, although it can exist with other peptide connection dextran or other cellular constituents.This term can show that also target variety is the main macromole kind (promptly on mole foundation, it is abundanter than any other single kind in composition) that exists.And target variety preferably contains the macromole kind of all existence of have an appointment 50% (on mole foundation) at least.Usually, isolating, purifying or pure substantially composition will contain 80% to all the macromole kinds more than 90% in composition.More preferably, make target variety be purified to basic homogeneous (promptly by the conventional sense method, can not detect and pollute kind) in composition, wherein composition is made up of single macromole kind substantially.
The error span of expression model experiment error in the measurement of all quantitative values amounts of being included in.II. general introduction
The invention provides the extract of rainbow conk (CV) purifying and activeconstituents thereof, purifying its method and the method for utilizing its immune stimulatory to reply.The activeconstituents of the extract of purifying of the present invention be one or more low-molecular-weight peptides connection dextran (0.7kDa to 5kDa and preferably 0.7kDa to 3kDa).Peptide connection dextran has kept the immunostimulatory properties of CV crude extract, and they are regularly edible as supplementary means in Chinese colony, has promoted at large to improve healthy and bring longevity.Recently, traditional extract more generally has been used for the treatment of the weak and tumour of general immunity.The cancer patients who accepts surgery, chemotherapy and/or radiotherapy is after prolonging the traditional CV extract of oral administration, and immunity and the state of health of having observed them are significantly increased.
Extract of the present invention, peptide connection dextran and activeconstituents thereof are used in patient's body and the stimulated in vitro immunne response as the CV crude extract in the traditional Chinese medical science conventional practice in a similar manner.In addition, the data that the application provides show that peptide connection dextran of the present invention can absorb by the intestines wall, allows to adopt the crude extract oral administration of traditional traditional Chinese medical science.Purity is higher, drug effect is bigger and/or the better advantage of reproducibility but extract of the present invention and peptide connection dextran and activeconstituents thereof have.Extract of the present invention, peptide connection dextran and activeconstituents thereof also can be used for further separation.For example, the data shown in show in an embodiment, and the peptide component of one or more peptide connection dextran has main immunostimulatory activity, though the dextran composition can give traditional immunostimulatory activity.So extract and peptide connection dextran can be used to prepare isolating peptide and activeconstituents thereof.
Though for implementing the present invention, cognitive mechanism is unwanted, can think, the mode of action obviously comprises the propagation of lymphocyte and medullary cell and the activation of scavenger cell.III. the extract of purifying of the present invention and peptide join dextran
The extract of purifying of the present invention comprises that at least a molecular weight of being determined by size exclusion chromatography is the peptide connection dextran of 0.7kDa to 5kDa.Described at least a peptide connection dextran has immunostimulatory activity.Immunostimulatory activity can be by hereinafter or reply significantly on the statistics in any analysis described in the embodiment and measure.
Preferably, the extract of purifying of the present invention comprises at least 50%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 60%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 70%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 80%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 85%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 90%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.The extract of purifying more of the present invention comprises at least 99%, molecular weight is the peptide connection dextran of 0.7kDa to 5kDa.
The dextran composition of peptide connection dextran comprises the glucose molecule that connects by 1 → 3 key.Some extracts contain several peptide connection dextran, and other contain single peptide connection dextran.In the extract that contains several peptide connection dextran, peptide component such as dextran composition can be identical or different in different peptidoglycans.In preferred extract, the molecular-weight average of peptide connection dextran is 0.7 to 3kDa.In some extracts, the molecular-weight average of peptide connection dextran is 0.7kDa or 1.0kDa.Molecular weight is no more than 3kDa and has superiority when guaranteeing by the intestines wall.The further feature of peptide connection dextran more of the present invention is solvable in water, ethanol and acetone, insoluble and shortage water absorbability in chloroform and two chloroforms.IV. prepare the extract of purifying of the present invention and the active water extract that peptide connection dextran I. prepares rainbow conk
Shown in the schema of Fig. 1, can be by forming the active water-phase extract that spissated extract prepares CV from the CV sporocarp that does with liquid solvent extracting sporocarp and the concentrated solution that obtains.In certain methods, the CV sporocarp that does is macerated, decolours, and in alkaline solution that dilutes such as 0.01N sodium hydroxide solution, boil.Other basic solutions such as potassium hydroxide also can utilize.Under this heating condition, the concentration of these alkaline aqueous solution extraction agents is preferably 0.1N to avoid possible loss of activity.After the extraction,, and clarify remaining product by centrifugal or additive method for example by removing by filter insoluble substance.Concentrate limpid supernatant liquor, and freeze-drying, standby before storage.
Freeze dried supernatant liquor is through identifying, its peptide is formed about by weight 4-6%, and is preferred 4.7%, and (in the experimental error scope) analyzed definite by Bradford.Preferred extract has the glucosylation compound by the determined 50%-60% of phenol sulfuric acid method (preferred 55%) by weight.Preferred extract has about 4-6% by weight, preferred about 4.8% uronic acid compound.2. the purifying or the partially purified active ingredient that prepare the CV extract
Schema in Figure 15 has shown the exemplary method for preparing partially purified extract.The thick CV extract of doing is water-soluble, and remove water-soluble less material by centrifugal.Cationic substance in the water-soluble CV extract of pH4 can and be removed by the Zeo-karb absorption.Then, by being further purified activeconstituents to the selectively any technology of electronegative molecule.Preferably utilize anionite-exchange resin DEAE Mierocrystalline cellulose.Partially purified component can be come further fractional separation by ethanol gradient fractional separation or according to their gel-filtration of molecular weight isolated molecule.Preferred molecular weight ranges is 0.7-3kDa.In the ethanol gradients in five steps, isolate active ingredient from institute in steps, except 95% water alcohol soluble substance.Utilize standard methods more known in the art such as chromatography can reach further purifying.For example, handle the dextran composition that from peptide component, to isolate peptide connection dextran by peptase.Handle by dextranase, can be from the dextran composition isolated peptides.The peptide fragment that can prepare peptide connection dextran by the digestion of proteolysis optionally.By gel electrophoresis, choose wantonly in bidimensional, can separate single peptide connection dextran and cut out decoupled band.V. determine the method for the immunostimulatory activity of the extract of purifying and activeconstituents
To different cell types, immunostimulatory activity has different effects.For jejune immunocyte, when it was subjected to the immunostimulant attack, a series of biochemical events had taken place, comprise that synthetic increase of phosphatide and divalent cation permeability improve.The synthetic of protein, RNA and final DNA taken place then soon.Last phenomenon is synthetic (this has finally caused cell fission), the basis of formation lymphocyte and the quantitative assay of medullary cell activatory of increasing of DNA.By adopting a kind of nucleotide precursor that mixes in the new synthetic DNA, contain tritium thymus pyrimidine ( 3H-Tdr) come the pulse labelling culture, thereby measure the synthetic of DNA.Determine to mix by scintillation counting 3H-Tdr is with respect to the amount of DNA synthesis rate.Scintillation counting has produced the data that are used as the former reactive count per minute of canonical measure mitogenesis (CPM) usually.By in control cultures, measuring CPM, make the CPM stdn that stimulates culture be called the ratio of stimulation index with generation.
Effect immunocyte such as scavenger cell can be secreted born of the same parents poison medium (NO for example when being activated by immunostimulant -) and cytokine (for example interleukin and the tissue necrosis factor).Because only stimulating on the basis in immunogen, scavenger cell secretes NO -, the NO of raising scavenger cell -Generation usually as the method for quantitative immunogenic immunostimulatory activity.With the process of immunostimulant incubation in, the high reactivity NO that scavenger cell produces -More stable nitrite (NO will be oxidized to very soon 2 -).The amount of the nitrite ion in the culture supernatants can be reacted by Griess and be measured then.
Immunostimulatory activity also can be measured in the body inner model of immunity.These models have the advantage in whole animal Horizontal Integration immunne response.The obtainable model that influence in the body of immunity is assessed comprises the cellularity (number of the composition cell of living) of important immune organs and the detection of delayed-type hypersensitivity.The recent tendency of immunology research is towards paying attention to utilizing stripped lymphproliferation response to develop to prove immunoreactive direction more 3,4Exsomatize and analyze the lymphopoietic ability that experiment has utilized cultivation,, and shown that with host immunity good relationship is arranged because in-vitro multiplication is the characteristic that lymphocyte has fully been discerned.After pharmacological agent finishes, put to death animal, reclaim immunologically competent cell.Then, cell is in the vitro culture certain period, and the cell that assessment contains the tritium thymus pyrimidine absorbs.Though, when cultivating, most of immunologically competent cells can breed, have to use immunostimulant, and for example Con A and LPS strengthen propagation to reach measurable level 3
Delayed hypersensitivity reaction and cell-mediated immunity have good relationship.The contact supersensitivity is a class delayed-type hypersensitivity; At the antigen of skin surface, mainly be haptens, absorb, process and be and pass T CD4 by the Langerhans cell +Lymphocyte, this lymphocyte cause finally that vasorelaxation and ear are swollen to rise.Intensive contact sensitizer is used for mouse as dinitrofluorobenzene (DNFB) and induces the reaction of tactiosensible property, and its intensity can contact by the treated with medicaments animal or with chemicals and regulate.Measuring the thickness of ear in 24 hours with digital calipers immediately with after the sensitization before the sensitization.The increase of ear thickness is the good indication of delay type supersensitivity.
In clinical and preclinical study, also can measure immunostimulatory activity to the patient, this shows that immunostimulant has the clinical efficiency that the enhancing cancer is treated routinely, from non-responsiveness recovering state immunologic function and the ability that strengthens the resistance that infects, this mainly is because the non-special stimulation of their immune defense system 2Non-specific immunity can be passed through antigen, or more directly strengthens by immunity is original.At molecular level, immunogen has the special structural units that is called antigenic determinant, can be crosslinked with the surface receptor of some immunocyte, and cause the clone to expand or activation.
During noticeable response, extract of the present invention or peptide connection dextran or its activeconstituents have immunostimulatory activity on causing statistics in a kind of above-mentioned analysis therein.Usually, will compare with contrast or placebo the reaction of extract or peptide connection dextran or its activeconstituents.VI. intestines permeability
The extract of purifying of the present invention, peptide connection dextran and activeconstituents thereof also can screen its permeability by intestines.This has when allowing oral administration.Screening can be adopted Caco-2 clone, and this is the good people's intestinal cells of a differentiation system of deriving from from the colon knurl, and its surrogate as the intestinal epithelial cells of in vitro study intestinal absorption is verified through strict.Bioavailability in the people and establish with the good relationship that Transwell  inserts between the permeability result that the Caco-2 individual layer in the fragment obtains.Can identify the molecular weight distribution and the immunogenicity 5,6 of the composition that can cross over the transhipment of Caco-2 individual layer by size exclusion chromatography and Bioexperiment recited above.Permeability is also measured in the animal model in vivo.VII. the in vitro method of pair cell reaction
CV extract, peptide connection dextran or activeconstituents can be used for many external or stripped methods.In certain methods, analyze best information in the dosage body that cell response to these reagent obtained making these reagent.In certain methods, CV extract, peptide connection dextran or activeconstituents screen other drug to the propagation of splenocyte or medullary cell or the excretory influence of scavenger cell as positive control.If positive control stimulates splenocyte or the propagation of medullary cell or the secretion of scavenger cell, and drug candidate not effect in parallel reactor can be reached a conclusion so, and testing drug is invalid.In additive method, the PMB that from the patient that immunologic derangement is arranged, obtains breeding.Come the ex vivo treatment lymphocyte with CV extract, peptide connection dextran or activeconstituents, return to the patient then.As other reagent that utilize stimulating immune system, as Con A or LPS, CV extract, peptide connection dextran or activeconstituents also can be used as the listing of scientific research reagent, to the active state of learned society's research cell or with comparing other reagent of finding stimulating immune system.VIII. stand the patient that treats
The patient who stands to treat includes the risk of immune deficiency, but does not also have the individuality of immune deficiency, and the patient who is just suffering from immune deficiency at present.Immune deficiency causes the susceptibility of opportunistic infection is strengthened.So, join the susceptibility decline of the patient of dextran or the treatment of its activeconstituents to opportunistic infection with CV extract or peptide.
These methods are specially adapted to treat the secondary immune deficiency that produces from elementary illness.In some disorders, secondary immune deficiency may be of short duration, and the patient may be along with elementary disease, becomes immunocompetence as the appropriate treatment of tuberculosis, leprosy.In other illnesss, secondary immune deficiency may become permanent, for example congenital rubella.So treatment plan can change according to elementary illness.Various disorders are relevant with secondary immune deficiency, and secondary immune deficiency may be caused by infection, malignancy disease, autoimmune disease, protein loss state, immunosuppressant therapy, surgical operation or anesthesia.
Can cause the infection of secondary immune deficiency to comprise: rubella, congenital rubella, measles, leprosy, tuberculosis, coccidiosis, chronic infection, acute viral infection, cytomegalovirus, multiple virus infection and repetition virus infection.
Can cause the malignancy disease of secondary immune deficiency to comprise: Huo Qijin (Hodgkin) disease, acute leukemia, chronic leukemia, non-lymphatic cancer and myelomatosis.
Can cause the autoimmune disease of secondary immune deficiency to comprise: systemic lupus erythematosus (SLE), rheumatoid arthritis and chronic active hepatitis.
Can cause the protein loss state of secondary immune deficiency to comprise: nephrotic syndrome and protein loss enteropathy.
Can cause the immunosuppressant therapy of secondary immune deficiency to comprise: reflunomide, cytotoxic drug, alkylating agent, metabolic antagonist, antithymocyte globulin, radiation, S-Neoral, phenytoin and Trolovol.
Can cause other illnesss of secondary immune deficiency to comprise: diabetes, alcoholic liver cirrhosis, nutritional trouble, burn, sarcoidosis, splenectomy, reaping hook cytopathy, uremia, aging, subacute sclerosing panencephalitis, mongolism (Down ' s syndrome), newborn infant and premature infant.VIII. methods of treatment, pharmaceutical composition and medication A. methods of treatment
In prophylactic application, with pharmaceutical composition or medicine with the amount that is enough to prevent, reduce or stops the immunologic derangement development to being easy to develop into immunologic derangement or this dangerous patient's administration being arranged.In treatment is used, with composition or medicine with the amount that is enough to reverse, stop or stops the immunologic derangement symptom to small part to suspecting development or having suffered from patient's administration of Immunological diseases.In prevention and treatment plan, usually join dextran or activeconstituents until reaching enough reactions with several dosed administrations Coriolus Versicolor P.E. of the present invention or peptide.But, in prevention and treatment plan, can single dosed administration extract of the present invention, peptide joins dextran or activeconstituents or the partially purified extract of CV, until reaching enough reactions.Usually, monitor therapy and give multiple dosage.In addition, treatment plan can utilize to treat other immune-mediated disorders in used those similar dosage, route of administration and administration frequency.
Can change the amount of the single dosage form that is produced after CV extract, peptide connection dextran or its activeconstituents combine with carrier substance according to disease, mammiferous kind and the specific administering mode of treatment.For any particular patient, " effective dose ", " pharmaceutically acceptable dosage " or " pharmaceutically acceptable amount " can be according to various factorss, comprise the activity, species, age, body weight of used specific compound, total healthy state, sex and the patient's that just treated diet; Time of administration and approach; Metabolism or excretory speed; The other drug of administration simultaneously or administration in the past; The type of Immunological diseases and severity; The seriousness of side effect, the patient is animal or people etc.Usually, the patient is the people, also can treat but non-human mammal comprises transgene mammal.
For any extract used in the method for the present invention, peptide connection dextran or activeconstituents, can estimate people's effective dose at first from non-human animal model.Utilize parameter known in the art, can determine effective dose by the clinician.Generally speaking, during beginning, dosage is lower than optimum effective dose slightly.Then, the increase by in a small amount improve dosage until reach effective dose (referring to, Merck diagnosis and treatment handbook, the 16th edition, 22 volumes, 1992, Berkow, the Merck research laboratory, Rathway, the New Jersey is incorporated herein by reference).
Dosage needs titration so that security and effect the best.The toxicity of compound as herein described and therapeutic efficiency be the standard drug method in the animal by experiment, for example by determining LD 50(cause death and reach the dosage of 50% test colony) and ED 50(the effective dosage of treatment in 50% test colony) is determined.Dose ratio between toxicity and the result of treatment is a therapeutic index, and can be expressed as LD 50With ED 50Between ratio.The compound that shows high therapeutic index is preferred.The data that obtain from these non-human animals research can be used to prepare does not have toxic dosage range when the people utilizes.The dosage of such compound is preferably placed at and comprises little or avirulent ED 50The scope of circulation composition within.Appropriate prescription, route of administration and dosage can by single doctor according to patient's illness select (referring to, Fingl etc. (1975) for example, the medicine principle (The Pharmacological Basis of Therapeutics) of treatment, the 1st chapter is incorporated herein by reference).
In certain methods, CV extract, peptide connection dextran or activeconstituents be with oral administration, dosage for every day 1.0mg to the 1000mg/kg body weight, dosage is preferably 20mg/kg to 50mg/kg.In additive method, CV extract, peptide connection dextran or activeconstituents be with oral administration, dosage for every day 0.001mg to 100mg/kg.CV extract, peptide connection dextran or activeconstituents can be with the every day of single dosage or with a plurality of dosed administrations every day.In certain methods, CV extract, peptide connection dextran or its activeconstituents be with oral administration, and every day, dosage was equivalent to the per kilogram of body weight every day CV crude extract of 50mg at least.B. pharmaceutical composition and medication
CV extract, peptide connection dextran and activeconstituents thereof can be separately with the form of pharmacologically acceptable salt or its hydrolysable precursors, or send or be administered to Mammals with pharmaceutical compositions, for example patient or individuality, this compound is with effective dose and appropriate carriers or one or more mixed with excipients in pharmaceutical composition.Solid oral dosage is a preferred pharmaceutical composition.Effectively scheme refers to, medicine or drug regimen be with significant quantity and frequency, and by suitable administration, can prevent with detecting, postpone, suppress or reverse the development of at least a immunologic derangement symptom at least.When " effective dose ", " pharmaceutically acceptable dosage " or " pharmaceutically acceptable amount " refer to suitable treatment plan administration, CV extract, peptide connection dextran or its activeconstituents are the result who reaches required, for example immune stimulatory is replied, the significant quantity of prevention, delay, inhibition or reverse immunologic derangement symptom or immunologic derangement development.
CV extract, peptide connection dextran or its activeconstituents can be used as pharmaceutical composition when being used for method of the present invention independent, and/or with various other pharmaceutically acceptable composition administrations.Pharmaceutical composition can be the form of solid (as powder, particle, drageeing, tablet or pill), semi-solid (as gel, syrup or ointment), liquid or gas (as aerosol or inhalation).
Being used for proper formula of the present invention can be Remington pharmaceutical science (Mack press, 1985), Philadephia, PA, the 17th edition) and Langer, science (1990) finds among the 249:1527-1533, is incorporated herein by reference.Pharmaceutical composition as herein described can be prepared in a usual manner, promptly mixes, dissolving, granulation, makes drageeing, grinding, emulsification, packing, embedding or freeze-dry process.
Tablet be prepared and be pressed into to CV extract, peptide connection dextran or activeconstituents can together with vehicle, diluent or carrier commonly used, or are mixed with elixir or make things convenient for the solution of oral administration.CV extract, peptide connection dextran or activeconstituents also can be mixed with the lasting dosage form that discharges etc.The administration of compound can be carried out by the whole bag of tricks, comprise oral, oral cavity, rectum, parenteral, intraperitoneal, in skin, tracheae, intravenously, subcutaneous and intramuscular administration.Oral administration is preferred.Compound can be with supply or sustained release formulation form topical rather than the administration of general mode.In addition, compound can the liposome administration.Further, compound can combine and eat with food, or with can consume liquid and combine and drink as beverage.
For oral administration, compound can be taked pill, tablet, capsule, powder or the particle form prepared in a usual manner.For oral administration, composition can be a fluid form, for example solution, suspension or emulsion.
For orally administering, compound can be taked tablet or the lozenge form prepared in a usual manner.
For inhalation, compound used according to the invention is to utilize suitable propelling agent with the form of aerosol spray from pressure-vessel, atomizer or injection sprinker, for example Refrigerant 12, trichlorofluoromethane, dichloro tetrafluoro ethane, carbonic acid gas or other suitable gas or deliver easily from the Diskus of no propelling agent.In the situation of pressurized aerosol, dose unit can be determined by the valve of sending metering is provided.The capsule and the film that are used for the gelatin of sucker or insufflator can be mixed with the powdered mixture that contains compound and suitable foundation cream such as lactose or starch.
Compound can be mixed with by injection, for example is used for administered parenterally by bolus injection or continuous infusion.The preparation of injection can be expressed as unit dosage form, and for example, the container of ampoule or multiple doses wherein adds sanitas.Composition can be taked the form as the suspension in oil base or the aqueous carrier, solution or emulsion, and can contain reagent preparation such as suspension agent, stablizer and/or dispersion agent.The composition of administered parenterally is mixed with Good Manufacturing Practice (GMP) regulations of oozing and meet fully U.S. food and Drug Administration such as aseptic, basic.
CV extract, peptide connection dextran or activeconstituents also can be mixed with rectal compositions, as the enema of suppository or delay, for example contain conventional suppository base, as theobroma oil, carbowax, polyoxyethylene glycol or other glycerine, all these dissolve in body temperature, but at room temperature remain solidified.
Except above-mentioned preparation, CV extract, peptide connection dextran or activeconstituents also can be mixed with supplies.So the preparation of long term can be by implantation (for example subcutaneous or intramuscular) or by the intramuscularly administration.So, for example, compound can with suitable polymkeric substance or hydrophobic substance (for example as the emulsion that can accept in the oil) or ion exchange resin, or as the microsolubility derivative, for example prepare (referring to for example as slightly soluble salt, Urquhart etc. (1984), Ann.Rev.Pharmacol.Toxicol.24:199; Lewis compiles, and 1981, sterilant and drug release, Plenum press, New York, N.Y., U.S. Patent number 3,773,919 and 3,270,960, be incorporated herein by reference).
Perhaps, can utilize other delivery systems of hydrophobic pharmaceutical compounds.Liposome and emulsion are the delivery vehicle of well-known dewatering medicament or the example of carrier.In certain methods, long-term round-robin, promptly the stealth liposome can utilize.At Woodle etc., U.S. Patent number 5,013 has briefly been described such liposome in 556, and its instruction is incorporated herein by reference.Compound of the present invention also can pass through controlled releasing method, continue method for releasing and/or delivery apparatus such as U.S. Patent number 3,845,770; 3,916,899; 3,536,809; 3,598,123 and 4,008, those described in 719 come administration, and these disclosures are incorporated herein by reference.
Pharmaceutical composition also can comprise suitable solid or gel phase carrier or vehicle.The such carrier or the example of vehicle comprise lime carbonate, calcium phosphate, various sugar, starch, derivatived cellulose, gelatin and polymer such as polyoxyethylene glycol.XI. embodiment
Mode by explanation rather than restriction provides the following examples.So,, but do not think limitation ot it by the application of the present invention of can giving an example of concentration, temperature and other varying parameters of selective reagents and reagent.Those professional and technical personnel of this area will recognize non-key parameter easily, and these parameters can change finishes invention as herein described.The preparation of the crude extract of embodiment 1 rainbow conk
Carry out following step and prepare rainbow conk (CV) crude extract.Rainbow conk (CV) sporocarp that does is macerated.Shred the CV sporocarp of macerating then.Remove pigment from the CV sporocarp of macerating, shredding.Then, extracting CV sporocarp.At alkaline aqueous solution, for example boil the CV sporocarp in sodium hydroxide or the potassium hydroxide and finish extracting.Alkaline aqueous solution less than 0.1N is preferred.After extraction steps, the preparation of thick CV extract can comprise one or more following steps: for example by removing by filter insoluble substance; For example by the centrifugal clarification extract; For example by the rotatory evaporator concentrated extract; For example by freezing extract of lyophilizer or cold dry extract.The thick CV extract that obtains can utilize or store for future use then.
Fig. 1 is the schema of the preparation scheme step of explanation CV crude extract.Macerate by in the 1L deionized water, soaking rainbow conk (CV) sporocarp that 300g is done.Behind the decantation deionized water, the CV sporocarp that chopping is macerated.Can remove pigment from the CV sporocarp of macerating, shredding.Submergence is spent the night in the 3L deionized water, realizes removing the pigment of the CV sporocarp of macerating, shredding.Carry out the extracting of CV sporocarp by boiling the CV sporocarp of macerating, shredding under the gentle constant agitation in the 0.01N of 2L sodium hydroxide.
Extract is poured on the coarse cloth, removes insoluble substance, wrapped up insoluble substance in the cloth.4000rpm made the supernatant liquor clarification that obtains in centrifugal 10 minutes.Then, by at 80 ℃ of rotary evaporations, the supernatant liquor of concentrating clarifying reduces 50% up to volume.Then, at-70 ℃ of freezing clarifications, spissated supernatant liquor, and freeze-drying.The thick CV extract that obtains has the dry mass of about 43g to 47g, and color is dark brown, and quality is fluffy.Thick CV extract can use or store for future use immediately.The physics and the chemical feature of the thick CV extract of example II
Analyze the CV crude extract, assess its solubleness, fusing point, degradation temperature and water absorbability.The method that is used for analyzing and each result are illustrated in Table I.
Table 1
The result Method
Solvable at the water camber In the glass test tube of 2 milliliters of solvents, dissolve 10 milligrams CV extract.Ultrasonic disruption 30 minutes.Measure absorbancy at the 254nm place.
In ethanol than more insoluble in the water As mentioned above, be ethanol except solvent
In acetone than more insoluble in the water As mentioned above, be acetone except solvent
Insoluble in chloroform As mentioned above, be chloroform except solvent
Insoluble in methylene dichloride As mentioned above, be methylene dichloride except solvent
There is not definite melting temperature 1. the differential scanning calorimetry has utilized Perkin Elmer Pyris 1 differential scanning calorimeter (having Pyris Manager software).Sample is positioned in the aluminium dish of sealing, under nitrogen purge with 10 ℃/minute rate of heating, scanning is (referring to Ford from 40 ℃ to 90 ℃, J.L. with Timmins P. Pharmaceutical Thermail Analysis-Techniques and Applications, Ellis Horwood Ltd., Chichester, West Sussex, England, 1989.) 2. thermogravimetric analysis has utilized the Perkin Elmer thermogravimeter TGA7 that has hot analyzer-controller TAC 7/DX.Sample is positioned in the open dish, scan from 40 ℃ to 110 ℃ (referring to Ford with 10 ℃/minute rate of heating, J.L. with Timmins P.Pharmaceutical Thermal Analysis-Techniques and App Applications, Ellis Horwood Ltd., Chichester, West Sussex, England, 1989.)
There is not definite degradation temperature 1. carry out differential scanning calorimetry 2. as mentioned above and carry out thermogravimetric analysis as mentioned above
Non-hygroscopic is observed changes in weight behind the following incubation of constant relative humidity (RH): in the weight increase＜5% after 14 days of incubation under the 10-70%RH Chu K.K.W. and Chow A.H.L., Pharm.Res.2000,17 (9): 1133-1137.
Analyze the CV crude extract with definite molecular-weight average, and neutral sugar, uronic acid and peptide/proteinic w/w percentage ratio.Also analyzed in the CV crude extract glucose as the existence of monose composition and the existence of dextran key (1 → 3).The peptide component that exists in the CV crude extract and the bonding of carbohydrate components have been identified.The method that is used to analyze and identifies and separately the result be illustrated in the Table II.
Table II
The result Method
Molecular-weight average: 2.6kDa molecular weight ranges: 0.5-40kDa Chromatogram
Peptide/protein: 4.7%w/w Bradford, M.M., Anal.Biochem.1976, the Bradford experiment of 72:248-254
Neutral sugar: 55%w/w Dubois, M. etc., Anal.Chem., 1956, the phenol sulfuric acid method of 28:350-356
Uronic acid: 4.8%w/w Blumenkrantz, N. etc., Anal.Biochem.1973, the carbazole of 54:484-489 (Carbozole) is analyzed
Glucose as the monose composition By Zhang Y.W. etc., 1997,63 (00): the determined acid hydrolysis of the method for 393-399 is by Kiyohara, H. etc., Carbohydr.Res., 1998, the determined alditol acetate derivatization of the method for 182:259-275 is by Kiyohara, H. etc., Carbohydr.Res., 1998, the described gas-chromatography of 182:259-275
(1 → 3) dextran By Hakomori, S., journal of biological chemistry, Tokyo, 1964, the determined methylation of the method for 55:205-208 is by Zhang Y.W. etc., 1997,63 (00): the determined acid hydrolysis of the method for 393-399 is by Kiyohara, H. etc., Carbohydr.Res., 1998, the determined alditol acetate derivatization of the method for 182:259-275 is by Kiyohara, H. etc., Carbohydr.Res., 1998, the determined GC/MS of the method for 182:259-275
With the close-connected peptide component of carbohydrate components The co-elute of two compositions in different stratographic analyses
Determine the molecular-weight average of thick CV extract by size exclusion chromatography.The 1-2mg/ml aqueous sample of 200 μ l is expelled in high performance liquid chromatography (HPLC) system (imitates the liquid chromatography (LC) system soon, Pharmacia), in Superose 12 10/30 posts, move, with 0.2M NaCl pH value of solution 7.0 wash-outs.Then, on elutriant application of sample to 2 * 40cm Superdex 75 10/30 posts, and with 200mM ammonium acetate pH7.0 wash-out.Collecting elutriant is the component of 1ml.Subsequently, with these components sample that performs an analysis.Monitor the UV absorbancy at the 210nm place by sepn process.
The molecular weight ranges of sample is 0.5-40kDa.The molecular-weight average of sample is 2.6kDa.Determine molecular weight with reference to the working curve that utilizes various carbohydrate standards to make up.
Fig. 2 A is the size exclusion chromatography spectrum, shows the elution profile of the protein component of CV crude extract.Protein content in the sample detects (referring to Table II) by the elution profile at the proteinaceous material of 254nm place monitoring.Fig. 2 B is the size exclusion chromatography spectrum of CV crude extract, shows the elution profile of the carbohydrate components of CV crude extract.Carbohydrate content in elutriant is tested by phenol sulfuric acid and is detected (referring to Table II).The propagation of in vitro study EXAMPLE III and the external mice spleen cell alive that contacts of CV crude extract
Put to death three ICR mouse by the neck dislocation.The spleen of the mouse of putting to death is taken out in anesthesia.By gentle each spleen separating Morr. cell of extruding on stainless steel sift.Merging is from the isolating splenocyte of each mouse, with the cell suspending liquid that obtains centrifugal 3 minutes with 1600rpm, and the tipping supernatant liquor.In cell precipitation, add about 6 milliliters dissolving damping fluid, to destroy the red blood corpuscle that exists in the precipitation.Use the residual dissolving damping fluid of PBS flush away subsequently.Then, the splenocyte that in complete cell culture medium, suspends.
Get rid of the viability of test assessment cell suspending liquid (referring to Parslow T.G. immunne response, Medical Immunology by trypan blue; Sities D.P., Terr A.I., Parslow T.G. compiles Appletonand Lange:London, 1997; The 63-73 page or leaf).The cell density of suspension liquid of living cell is adjusted to 2 * 10 6Cells/ml.100 μ l cell suspending liquids are inoculated into the droplet flat board (NUNC in 96 holes TM) on.
Then, the cell of inoculation is contacted with following material: the sample of the CV crude extract of (1) 100 μ l (final concentration 1-500 μ g/ml), the concanavalin A of (2) 100 μ l (Con A) is (final concentration is 0.016-4.0 μ g/ml) (Sigma), as the substratum of positive control or (3) 100 μ l, as negative control.
Then, with the 95%O of exposing cell at humidification 2And 5%CO 237 ℃ of following incubations are 72 hours in the air.The 54th hour, with 0.5 μ Ci/10 μ l/ hole 3H-methyl thymus pyrimidine pulse labelling cell.Then at the 72nd hour, with cell harvestor with cell harvesting on glass fiber filter paper, use scintillation counting to determine to be mixed with respect to DNA is synthetic 3The amount of H-methyl thymus pyrimidine.By the CPM in the negative control cell with count per minute (CPM) stdn of exposing cell to produce stimulation index.With in the exposing cell 3The cell of H-methyl thymus pyrimidine mixes number (count per minute (CPM)) and counts the calculating stimulation index divided by mixing of negative control cell.
When low Con A concentration, be dose-dependent with the proliferation activity of the splenocyte of CV extract-treated mouse.When ConA concentration is 50 μ g/ml, with the proliferation activity of the splenocyte of CV extract-treated mouse 20 times of contrast.Being 100 μ g/ml with concentration handles to the CV crude extract of 350 μ g/ml, and to stimulate the proliferative of the splenocyte of mouse to react with the about 1 μ g/ml of concentration to the Con A of about 3 μ g/ml be similar.With results expression is stimulation index (referring to Fig. 3).EXAMPLE IV and the external mouse medullary cell that contacts of CV crude extract
Put to death 5 ICR mouse by the neck dislocation.The femur of putting to death mouse is taken out in anesthesia.Remove the muscle that is connected with femur as much as possible, get the marrow plug.Load onto PBS flushing marrow plug with the 2ml syringe of being furnished with the 25G syringe needle.Merging is from the isolating medullary cell of each marrow plug.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.The density of regulating suspension liquid of living cell is to produce 4 * 10 6The cell suspending liquid of individual cell/ml.The cell suspending liquid of 100 μ l is seeded in the droplet flat board (NUNC in 96 holes TM) on.
Then, cell is contacted with following material: the CV crude extract sample of (1) 100 μ l (final concentration 25-200 μ g/ml), the lipopolysaccharides of (2) 100 μ l (LPS) is (final concentration 2.5-20 μ g/ml) (Sigma), as positive control, or the substratum of (3) 100 μ l, as negative control.With the contact cell at 95%O 2And 5%CO 2Atmosphere in 37 ℃ of following incubations 120 hours.The 104th hour, with 0.5 μ Ci/10 μ l/ hole 3H-methyl thymus pyrimidine pulse labelling cell.The 120th hour, harvested cell, and as above EXAMPLE III is determined stimulation index.
Fig. 4 has illustrated the cultivation effect with the mouse medullary cell of CV crude extract or the external contact separation of LPS.The result is expressed as stimulation index.When the CV crude extract is presented at its concentration and is 200 μ g/ml, 40 times of bone marrow proliferations.The reaction of the proliferative response that medullary cell contacts with the CV crude extract during than the LPS of similar relative concentration is bigger.EXAMPLE IV and the external mouse macrophage that contacts of CV crude extract
10 ICR mouse of Thiovanic acid salt brine solution peritoneal injection with the 3%w/v of lml.After 3 days, put to death mouse by the neck dislocation.Open peritonaeum and gather in the crops scavenger cell with PBS lavation space.Merge the PBS irrigating solution that each puts to death mouse.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.The density of regulating suspension liquid of living cell is to produce 4 * 10 6The cell suspending liquid of cell/ml.100 μ l cell suspending liquids are seeded in the droplet flat board (NUNC in 96 holes TM) on.
95%O at humidification 2And 5%CO 2Atmosphere in, allow under 37 ℃ in the cell to adhere to 1 hour in the bottom in the hole of droplet flat board.Then, carefully remove supernatant liquor in the hole.Then, cell is contacted with following material: (1) 200 μ l concentration is the CV crude extract of 25-200 μ g/ml, and (2) 200 μ l concentration are the LPS (Sigma) of 0.125-1 μ g/ml, as positive control, or the complete cell culture medium of (3) 200 μ l, as negative control.With the cell of contact at the 95%O of humidification 2And 5%CO 2Atmosphere in 37 ℃ of following incubations 24 hours.
The 24th hour, determine by Griess reaction the nitrate that exists in the acellular substratum amount (referring to Green L.C. etc., the analysis of the nitrate in the biofluid, nitrite and [15N] nitrate, Anal.Biochem., 1982,126:131-138).From the hole of each droplet flat board, draw the aliquots containig of the acellular substratum of 150 μ l, and the Griess reagent react of the Kong Zhongyu of fresh droplet flat board 50 μ l 10 minutes.Then, at the 540nm place, utilize droplet plate reader (BTI, ELX800) absorbancy of measurement aliquots containig.
Fig. 5 has illustrated with CV crude extract or the external mouse peritoneal macrophages secretion nitrogen protoxide that contacts of LPS and has improved.The proliferation activity of the mouse peritoneal macrophages of handling with the CV crude extract causes the nitrogen protoxide secretion to improve, and is dose-dependent in CV concentration during less than about 100 μ g/ml.Surpass the not raising of proliferation activity of the cell that the CV crude extract of 100 μ g/ml contact with concentration.The proliferation activity of LPS is dose-dependent when low LPS concentration.The in vitro study example VI is to normal mouse administration CV crude extract research and design
20 ICR mouse are divided into 4 groups, every group each 5.As shown in Table III, group 1 usefulness CV crude extract intraperitoneal administration is handled; The administration of the common salt solution intraperitoneal of group 2 usefulness is handled, as negative control; Group 3 usefulness CV crude extract oral administrations are handled; Use the deionized water oral administration with group 4, as negative control.Utilize the interior pipe of stomach to force hello mouse to finish oral administration.
Table III has shown the dosage of each group and the plan of taking medicine.Mouse in the 4th day execution group 1 and group 2.Mouse in the 8th day execution group 3 and group 4.
The 1st day, the CV crude extract of weighing, and be dissolved in the deionized water, the concentration of regulator solution is to 5mg/ml.With solution ultrasonication 30 minutes, removed any insoluble substance in centrifugal 10 minutes with 4000rpm, be filled in the aseptic bottle by 0.22 aseptic μ m strainer (IWAKI) then.With solution be stored in 4 ℃ standby.
Table III
Treatment group The mouse number CV dosage The CV plan of taking medicine Route of administration
????1 ????5 50mg/kg/ days (the 5mg/ml injection of solution of 0.25ml is gone in the mouse of about 25g) 1st, 2 and 3 days Peritoneal injection
????2 ????5 0.25ml aseptic common salt solution pH7.4 1st, 2 and 3 days Peritoneal injection
????3 ????5 50mg/kg/ days (the 5mg/ml solution of 0.25ml is oral to be fed in the mouse of about 25g) 1-7 days Oral
????4 ????5 0.25ml deionized water 1-7 days Oral
1. intraperitoneal administration CV crude extract is to the influence from the mice spleen cell proliferation in vivo alive of normal mouse
When relatively the time, mouse (group 1) intraperitoneal administration CV crude extract having been improved the number 58.6% (referring to Fig. 6 A) of the splenocyte of living in the body with control mice (group 2).As above described results of EXAMPLE III and separating Morr. cell.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.2. intraperitoneal administration CV crude extract is to the influence of the mouse medullary cell vitro proliferation that stimulates from the LPS of normal mouse
Shown the proliferation activity (referring to Fig. 6 B) that comparison stimulates according to the higher stripped LPS of medullary cell of mouse (group 2) with the medullary cell of the mouse of CV crude extract intraperitoneal administration (group 1).As above the described results of EXAMPLE IV with separate medullary cell.As above the described test of EXAMPLE IV CV crude extract is to the proliferation activity of medullary cell.3. oral administration CV extract is to the influence from the mice spleen cell proliferation in vivo alive of normal mouse
When relatively the time, having improved the number 40% (referring to Fig. 7 A) of the splenocyte of living in the body for mouse (group 3) oral administration CV crude extract with control mice (group 4).As above described results of EXAMPLE III and separating Morr. cell.Preparation cell suspending liquid, and the as above viability of the described test cell suspension of EXAMPLE III.4. oral administration CV extract is to the influence of the medullary cell vitro proliferation that stimulates from the LPS of normal mouse
Mouse (group 3) medullary cell handled with CV crude extract oral administration shown proliferation activity (referring to Fig. 7 B) that comparison stimulates according to the higher stripped LPS of medullary cell of mouse (group 4) as above the described results of EXAMPLE IV with separate medullary cell.As above the described test of EXAMPLE IV CV crude extract is to the proliferation activity of medullary cell.Example VII A is to the mouse of non-responsiveness or the mouse administration CV crude extract research and design of severe non-responsiveness
40 ICR mouse are divided into 8 groups, and every group is 5.The 1st day, the mouse that comes immunosuppression group 1-4 by the endoxan of peritoneal injection 20mg/kg.At the 1st day, come the mouse (referring to the endoxan dosage of Table IV and the plan of taking medicine) of serious immunosuppression group 5-8 by the endoxan of peritoneal injection 100mg/kg equally.After immunosuppression the 5th, 6 and 7 day, group 1 usefulness CV crude extract peritoneal injection administration processing; The normal common salt solution intraperitoneal administration of group 2 usefulness is handled.After immunosuppression 1-7 days, the processing of group 3 usefulness CV crude extract oral administrations, and organize 4 usefulness deionized waters and handle.After serious immunosuppression 1-7 days, the processing of group 5 usefulness CV crude extract oral administrations; Handle with group 6 usefulness deionized waters.After serious immunosuppression 1-14 days, the processing of group 7 usefulness CV crude extract oral administrations; Handle with group 8 usefulness deionized waters (referring to the CV crude extract dosage of Table IV, the plan of taking medicine and route of administration).Group 2,4,6 and 8 is negative control group.The mouse of the 8th day execution group 1-6.The mouse of group 7 and group 8 was put to death in the time of the 15th day.
With the endoxan injection of solution group 1-4 that is prepared as follows.Buy endoxan 200mg/ bottle (Endoxan-Asta) from Asta Medica.By specification instructs, and redissolves endoxan with aseptic deionized water.Concentration with aseptic common salt solution regulator solution arrives 1mg/ml, five equilibrium in aseptic bottle, and be stored in-80 ℃.Preparation endoxan solution under aseptic condition.The 1st day, endoxan solution is thawed, be injected in the mouse of group 1-4.
With as the endoxan injection of solution group 5-8 of preparation as described in to group 1-4, except strength of solution being adjusted to 5mg/ml.The 1st day, endoxan is thawed, and be injected in the mouse of group 5-8.
As above example VI is described, and preparation CV crude extract is used for intraperitoneal or oral administration.
Table IV
Treatment group The mouse number Endoxan dosage and the plan of taking medicine CV dosage and the plan of taking medicine Route of administration
????1 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone into the mouse of about 25g) 5th, 6 and 7 days, 50mg/kg/ days (the 5mg/ml solution of 0.25ml is oral to be fed in the mouse of about 25g) Peritoneal injection
????2 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 5th, 6 and 7 days, the normal aseptic salt pH7.4 of 0.25ml (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) Peritoneal injection
????3 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-7 days, 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) Oral
????4 ????5 The 1st day, 20mg/kg/ days (injection of solution of the 1mg/ml of 0.5ml is gone in the mouse of about 25g) 1-7 days, the 0.25ml deionized water Oral
????5 ????5 The 1st day, 100mg/kg/ days (the 5mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-7 days, 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) Oral
????6 ????5 The 1st day, 100mg/kg/ days (the 5mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-7 days, the 0.25ml deionized water Oral
????7 ????5 The 1st day, 100mg/kg/ days (the 5mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-14 days, 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) Oral
????8 ????5 The 1st day, 100mg/kg days (the 5mg/ml injection of solution of 0.5ml is gone in about 25g mouse) 1-14 days, the 0.25ml deionized water Oral
1. intraperitoneal administration CV crude extract is to the influence from the mice spleen cell proliferation in vivo alive of non-responsiveness mouse
Compare with control mice (group 2), immunosuppressed mice (group 1) intraperitoneal administration CV crude extract has been significantly improved the number (p＜0.001) (referring to Fig. 8 A) of the splenocyte of living in the body.As results and separating Morr. cell as described in the EXAMPLE III.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.2. intraperitoneal administration CV crude extract is to the influence from the mouse medullary cell proliferation in vivo alive of non-responsiveness mouse
The medullary cell comparison of the mouse (group 1) of handling with the administration of CV crude extract intraperitoneal has significantly improved the number (p＜0.05) (referring to Fig. 8 A) of the medullary cell of living in the body according to the medullary cell of mouse (group 2).As results as described in the EXAMPLE IV with separate medullary cell.Viability as test medullary cell as described in the EXAMPLE III.3. oral administration (plan of taking medicine in 7 days) CV crude extract is to the influence of the mice spleen cell proliferation in vivo of living from the mouse of non-responsiveness
Compare with control mice (group 4), can not improve the number (referring to Fig. 8 B) of the splenocyte of living in the body to immunosuppressed mice (group 3) oral administration CV crude extract.And as results and separating Morr. cell as described in the EXAMPLE III.The preparation cell suspending liquid, and as the viability of test cell suspension as described in the EXAMPLE III.4. oral administration (plan of taking medicine in 7 days) CV extract is to the influence from the bone marrow cells in mice proliferation in vivo alive of the mouse of non-responsiveness
The medullary cell of the mouse (group 3) of handling with CV crude extract oral administration and the medullary cell of control mice (group 4) have relatively significantly improved the number (p＜0.005) (referring to Fig. 8 B) of medullary cell alive in the body.And as results as described in the EXAMPLE IV with separate medullary cell.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.5. oral administration CV crude extract (plan of taking medicine in 7 days) is to the influence from the mice spleen cell proliferation in vivo alive of the mouse of severe non-responsiveness
Compare with control mice (group 6), mouse (group 5) the oral administration CV crude extract of severe non-responsiveness has been improved the number of the splenocyte of living in the body.But the quantity of raising is not significantly (referring to Fig. 8 C) statistically.As results and separating Morr. cell as described in the EXAMPLE III.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.6. oral administration CV crude extract (plan of taking medicine in 7 days) is to the influence from the mouse medullary cell proliferation in vivo alive of the mouse of severe non-responsiveness
With control mice (group 6) relatively, the oral administration CV crude extract of the mouse (group 5) of severe non-responsiveness has been significantly improved the number (p＜0.01) (referring to Fig. 8 C) of the medullary cell of living in the body.And as results as described in the EXAMPLE IV with separate medullary cell.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.7. oral administration (plan of taking medicine in 14 days) CV crude extract is to the influence from the mice spleen cell proliferation in vivo alive of the mouse of severe non-responsiveness
When with control mice (group 8) comparison, immunosuppressant mouse oral administration CV crude extract is not increased the number (referring to Fig. 9 A) of the splenocyte of living in the body.As results and separating Morr. cell as described in the EXAMPLE III.The preparation cell suspending liquid is as the viability of test cell suspension as described in the EXAMPLE III.8. oral administration (plan of taking medicine in 14 days) CV extract is to the influence from the mouse medullary cell proliferation in vivo alive of the mouse of severe non-responsiveness
When with control mice (group 8) relatively the time, the medullary cell of the mouse (group 7) of handling with CV crude extract oral administration has significantly increased the number (P＜0.05) (referring to Fig. 9 A) of medullary cell alive in the body.As results as described in the EXAMPLE IV with separate medullary cell.As described in EXAMPLE IV, test the proliferation activity of CV crude extract to medullary cell.9. oral administration CV extract (plan of taking medicine in 14 days) is to stimulating the influence of splenocyte vitro proliferation from the Con of serious immunosuppressant mouse
The splenocyte comparison of the mouse (group 7) of handling with CV crude extract oral administration has shown bigger vitro proliferation activity (referring to Fig. 9 B) according to the splenocyte of mouse (group 8).As results and separating Morr. cell as described in the EXAMPLE III.As described in EXAMPLE III, test the proliferation activity of CV crude extract to splenocyte.10. the influence of oral administration CV extract medullary cell vitro proliferation that the LPS from the mouse of severe non-responsiveness is stimulated
The medullary cell comparison of the mouse (group 7) of handling with CV crude extract oral administration has shown the proliferation activity (p＜0.05) (referring to Fig. 9 C) that bigger stripped LPS stimulates according to the medullary cell of mouse (group 8).As results as described in the EXAMPLE IV with separate medullary cell.As described in EXAMPLE IV, test the proliferation activity of CV crude extract to medullary cell.Dose response research research and design in the mouse of example VII A I non-responsiveness
20 ICR mouse are divided into 4 groups, every group each 5.The 1st day, the mouse (referring to the endoxan dosage of Table V and the plan of taking medicine) that comes immunosuppression group 1-4 by peritoneal injection 20mg/kg endoxan.Behind the administration endoxan 1-7 days, with 5,20 and 50mg/kg/ days CV crude extract oral administration treatment group 1,2 and 3 mouse.After the endoxan administration 1-7 days, with the mouse (referring to the CV crude extract dosage of Table V and the plan of taking medicine) of deionized water treatment group 4.Group 4 is negative control group.The mouse of group 1-4 was put to death at the 8th day.
Preparation endoxan and administration described in example VII A.
Preparation is used for oral administration 50mg/kg/ days CV crude extract described in example VI.As preparation oral administration 5mg/kg/ days and 20mg/kg/ days CV extracts as described in the example VI, except strength of solution is adjusted to 0.5mg/ml and 2mg/ml respectively.
Table V
Treatment group The mouse number Endoxan dosage and the plan of taking medicine CV dosage and the plan of taking medicine Route of administration
????1 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5mg is gone in the mouse of about 25g) 1-7 days, 5mg/kg/ days (the oral mouse that feeds about 25g of the 0.5mg/ml solution of 0.25ml) Oral
????2 ????5 The 1st day, 10mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-7 days, 20mg/kg/ days (the oral mouse that feeds about 25g of the 2mg/ml solution of 0.25ml) Oral
????3 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) 1-7 days, 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) Oral
????4 ????5 The 1st day, 20mg/kg/ days (injection of solution of the 1mg/ml of 0.5ml is gone in the mouse of about 25g) 1-7 days, the 0.25ml deionized water Oral
1. the CV extract of oral administration various dose is to the influence from the mice spleen cell proliferation in vivo alive of immunosuppressant mouse
When with control mice (group 4) relatively the time, to mouse (group 1) with 5mg/kg/ days and to mouse (group 2) with 20mg/kg/ days oral administration CV crude extracts, improved the number (referring to Figure 10) of the splenocyte of living in the body in dose-dependent mode.When with control mice (group 4) relatively the time, mouse (group 3) oral administration CV crude extract can not increased in 50mg/kg/ days the number (referring to Figure 10) of the splenocyte of living in the body.The result who occurs among the data of finding in group 3 the mouse and example VII A I as discussed above and Fig. 8 A is consistent.
Results and separating Morr. cell described in EXAMPLE III.Preparation cell suspending liquid, and the as above viability of the described test cell suspension of EXAMPLE III.2. the CV extract of oral administration various dose is to the influence from the mouse medullary cell proliferation in vivo alive of immunosuppressant mouse
When with control mice (group 4) comparison, to mouse (group 1) with 5mg/kg/ days, mouse (group 2) with 20mg/kg/ days, with 50mg/kg/ days oral administration CV crude extracts, has been improved the number (referring to Figure 10) of the medullary cell of living in the body to mouse (group 3) in dose-dependent mode.When with control group mice (group 4) relatively the time, to organizing the propagation (p＜0.01) that 2 mouse oral administration CV extract has improved medullary cell; With when with control mice group (group 4) relatively the time, to organizing the propagation (p＜0.001) that 3 mouse oral administration CV extract has improved medullary cell.
As results as described in the EXAMPLE IV with separate medullary cell.The preparation cell suspending liquid, and as the viability of test cell suspension as described in the EXAMPLE III.Example I X is to the mouse of normal mouse, non-responsiveness and the mouse oral administration of severe non-responsiveness: the immunne response of pair cell mediation influence research and design
Utilize mouse model to determine the increase of cell-mediated immune responses.The contact supersensitivity is a cell-mediated immune responses.This model based is the contact supersensitivity research of standard, and this depends on the expression of the measurement of mouse ear swelling being determined the contact supersensitivity.
Then, 36 mouse are divided into 6 groups, every group each 6.In order to allow to identify in the future individuality, each mouse of mark on its tail.Group 1 and group 2 are normal mouses; Group 3 and 4 is mouse of non-responsiveness and to organize 5 and 6 are mouse of severe non-responsiveness.In the time of 1-7 days, organize 1,3 and 5 usefulness 50mg/kg/ days CV crude extract oral administration and handle.At 1-7 days, group 2,4 and 6 usefulness 0.25ml deionized water oral administrations were handled.At the 3rd and 4 day, all 36 mouse were with 2,4-dinitrobenzene-1-fluorobenzene (DNFB) sensitization.At the 7th day, attack all 36 mouse with DNFB.At the 8th day, all 36 mouse are carried out ear measure (referring to Table VI).
The described preparation of example VI CV crude extract is used for organizing 1,3 and 5 oral administrations as mentioned.The described administration CV of example VI and Table III crude extract (simultaneously referring to CV crude extract dosage in the Table VI and the plan of taking medicine) as mentioned.
Example VII A is discussed as mentioned, and the preparation endoxan is used for storage and administration.As mentioned described in example VII A and the Table IV, the mouse that administration 20mg/kg came immunosuppression group 3 and 4 in the 1st day.Described in example VII A and the Table IV, the 1st day administration 100mg/kg comes the mouse (referring to the endoxan dosage of Table VI and the plan of taking medicine) of serious immunosuppression group 5 and 6 as mentioned.
At the 3rd and the 4th day, following usefulness 2,4-dinitrobenzene-all 36 mouse of 1-fluorobenzene (DNFB) sensitization.By the DNFB of the 0.25%w/v of 25 μ l being applied directly to the belly that each mouse is shaved light, and finish contact by the flippers that the DNFB with the 0.25%w/v of 5 μ l is applied directly to each mouse with suction pipe.At the 7th day, following usefulness 2,4-dinitrobenzene-1-fluorobenzene (DNFB) is attacked all 36 mouse.By contact being finished in the both sides that the DNFB of the 0.20%w/v of 10 μ l is applied directly to each each ear of mouse with suction pipe.At the 8th day, utilize digital calipers, promptly the Mitutoyo digital micrometer carries out the ear measurement to ear thickness.
Table VI
Treatment group The mouse number Dosage of endoxan (intraperitoneal administration) and the plan of taking medicine DNFB dosage and the plan of taking medicine CV dosage (oral administration) and the plan of taking medicine
1 6 N/A The the 3rd and 4 day, the DNFB of the 0.25%w/v of 25 μ l was coated in the belly and the 5 μ l that shave light and is coated on each flippers.The 7th day, the DNFB of the 0.2%w/v of 10 μ l was coated in each ear both sides.The 8th day, measure ear thickness. 1-7 days, 50mg/kg/ days (0.25ml) (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml)
2 6 N/A Identical with group 1 1-7 days, the 0.25ml deionized water
3 6 The 1st day, 20mg/kg/ days (injection of solution of the 1mg/ml of 0.5 ml is gone in the mouse of about 25g) Identical with group 1 1-7 days, 50mg/kg/ days (the oral mouse that feeds 25g of the 5mg/ml solution of 0.25ml)
4 6 The 1st day, 20mg/kg/ days, (injection of solution of the 1mg/ml of 0.5ml is gone in the mouse of about 25g) Identical with group 1 1-7 days, the 0.25ml deionized water
5 6 The 1st day, 100mg/kg/ days (the 5mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) Identical with group 1 1-7 days, 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml)
6 6 The 1st day, 100mg/kg/ days (the 5mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) Identical with group 1 1-7 days, the 0.25ml deionized water
1. handle the result of normal mouse with the administration of CV extract oral
Shown in mouse ear swelling was measured, normal mouse (group 1) comparison had more remarkable high hypersensitivity reaction (p＜0.05) (referring to Figure 11) according to mouse (group 2).2. handle the result of immunosuppressed mice with the administration of CV extract oral
Shown in mouse ear swelling was measured, immunosuppressed mice (group 3) comparison had more remarkable high hypersensitivity reaction (p＜0.05) (referring to Figure 11) according to mouse (group 4).
The hypersensitivity reaction of immunosuppressant mouse (group 3) is significantly different with the hypersensitivity reaction in the control mice (group 2).3. handle the result of serious immunosuppressant mouse with the administration of CV extract oral
Measure as mouse ear swelling, serious immunosuppressant mouse (group 5) comparison has more remarkable high hypersensitivity reaction (p＜0.001) (referring to Figure 11) according to mouse (group 6).
The hypersensitivity reaction (p＜0.001) of serious immunosuppressed mice (group 5) than immunosuppressed mice (group 3) (p＜0.05) or in normal mouse (group 1) (p＜0.05) observed hypersensitivity reaction bigger.Embodiment X is to long-term (30 days) the oral administration CV extract research and design of normal mouse
10 ICR mouse are divided into two groups, every group each 5.As shown in Table VII, group 1 usefulness CV crude extract oral administration is handled, and organizes 2 usefulness deionized water oral administrations and handle, as negative control.Table VII shows the dosage of each group and the plan of taking medicine.The mouse of two groups was put to death in the time of the 31st day.Preparation CV crude extract, storage and administration (simultaneously referring to Table VII) are discussed in the example VI as mentioned.
Table VII
Treatment group The mouse number CV dosage The CV plan of taking medicine Route of administration
????1 ????5 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25 ml) 1-30 days Oral
????2 ????5 0.25ml deionized water 1-30 days Oral
1. long-term oral administration (30 days) CV crude extract is to the influence from the mice spleen cell proliferation in vivo alive of normal mouse
When relatively the time, not significantly improving the number (referring to Figure 12 A) of the splenocyte of living in the body to mouse (group 1) oral administration CV crude extract with control mice (group 2).As results and separating Morr. cell as described in the EXAMPLE III.Preparation cell suspending liquid, and the viability of the described test cell suspension of EXAMPLE III as mentioned.2. the influence of the mouse medullary cell proliferation in vivo that long-term oral administration CV crude extract stimulates the LPS from normal mouse
When relatively the time, can significantly not increasing the number (referring to Figure 12 A) of the medullary cell of living in the body to mouse (group 1) oral administration CV crude extract with control mice (group 2).As results as described in the EXAMPLE IV with separate medullary cell.The viability of the described test medullary cell of EXAMPLE III as mentioned.3. long-term oral administration CV crude extract is to the influence from the mice spleen cell vitro proliferation alive of normal mouse
The proliferative response comparison of the splenocyte of handling with CV crude extract (group 1) is according to the proliferative response bigger (referring to Figure 12 B) of mouse (group 2).As results and separating Morr. cell as described in the EXAMPLE III.Preparation cell suspending liquid, and the viability of the described test cell suspension of EXAMPLE III as mentioned.Stimulate splenocyte with ConA, and EXAMPLE V is discussed the calculating stimulation index as mentioned.4. the influence of the medullary cell vitro proliferation that long-term oral administration CV crude extract stimulates the LPS from normal mouse
The medullary cell comparison of the mouse (group 1) of handling with CV crude extract oral administration has shown the proliferation activity (referring to Figure 12 C) that bigger stripped LPS stimulates according to the medullary cell of mouse (group 2).
As results as described in the EXAMPLE IV with separate medullary cell.The described test of EXAMPLE IV CV crude extract is to the proliferation activity of medullary cell as mentioned.The acute toxicity of embodiment XI oral administration CV crude extract
The 1st day,, observed the toxicity signal 14 days with 5 ICR mouse that the CV crude extract oral administration of 1g/kg is handled each sex.In the observation period, do not have dead mouse, and, do not have one to show any toxicity signal in 10 mouse in the whole observation period.
Example VI is described as mentioned, and preparation CV crude extract is used for 10 mouse oral administrations (except that concentration).Disposable administration CV crude extract.
To the CV crude extract of 10 mouse administrations are no contaminated with endotoxins.The CV crude extract sample of 2mg/ml is carried out the intracellular toxin test.Utilize Limulus AmebocyteLysate (LAL) test kit (Cape Cod Ltd.) to test, limit of detection is 0.25EU/ml LAL.Embodiment XII negative charge density is to the immunocompetent influence of peptide connection dextran
To compare by the external immunocompetence that anion-exchange chromatography method fractional separation is C1D2, C1D3, C1D4 and C1D5 to the poly-dextran of the CV peptide in the various negative charge density groups.Figure 13 has illustrated the propagation with the external mice spleen cell alive that contacts of C1D2, C1D3, C1D4 and C1D5.In various ingredients, observed big immunizing power difference.The peptide of high negative electricity density connection dextran than low negative electricity density components and not the CV extract of fractional separation showed higher maximum activity (being steady level) and potentiality (i.e. the precipitous rising of activity when hanging down sample concentration).This shows that negative electricity density is the immunogenic important determinant of the peptide connection dextran of CV derivation.EXAMPLE III is described has as mentioned assessed external immunocompetence.Embodiment XIII molecular weight is to the immunocompetent influence of peptide connection dextran
Component C1E8, C1E6, C1E4, C1E2 and C1E0 are determined external immunocompetence.Figure 14 illustrates and causes after the mouse peritoneal macrophages contacts with C1E8, C1E6, C1E4, C1E2 and C1E0 are external that the nitrogen protoxide secretion increases.Immunocompetence is unqualified to special molecular weight ranges.C1E8, C1E6, C1E4, C1E2 and C1E0 provide similar dose response figure, reach stationary state between 100 and 200 μ g/ml.Maximum (steadily) active molecular weight along with component improves and improves.The external immunocompetence of the described assessment of EXAMPLE III as mentioned.Embodiment XIV prepares the partially purified extract of rainbow conk
The partially purified preparation method of extract of rainbow conk (CV) is with the CV crude extract dissolving by the described method preparation of example I, carries out two step chromatographic separation and separates with a step alcohol grading.CV crude extract solution is carried out the first step chromatography, and CM cellulose column for example is with the decationize material.The elutriant that obtains is carried out the second step chromatography, and for example the DEAE cellulose column is with in conjunction with anionic species.This elutriant separates according to molecular weight then, and scheme is separated or gel-filtration for for example alcohol grading.The elutriant that obtains, the partially purified extract of CV can be further purified by any purification technique, decationize from the partially purified extract of CV.
Figure 15 illustrates that the activeconstituents at the thick CV extract of Fig. 1 is further purified the schema of used step in the scheme.To be dissolved in the deionized water as the CV crude extract of the 1.0g of example I method preparation.Dissolved CV crude extract under 4000rpm centrifugal 10 minutes is removed insoluble substance.Then, further remove insoluble particle by 0.45 μ m filter paper (IWAKI) filtering supernatant.
With 0.5M NaOH washing 3 times, Fibrous (Sigma) the CM Mierocrystalline cellulose open glass post (Bio-Rad) of each 30 minutes balance 600ml, then with 0.5MHCl washing 3 times, each 30 minutes.Use the deionized water balance post.
Then, supernatant liquor is crossed post, collect elutriant (referring to the buffer conditions of Figure 15).Analyze composition activity.To have active component C1 and cross the DEAE cellulose column, collect elutriant (referring to the buffer conditions of Figure 15).Analyze composition activity.Component C1D5 carries out alcohol grading and separates (referring to the buffer conditions of Figure 15), and as utilizing the activity of the component that the mice spleen cell analysis obtains as described in the EXAMPLE III.The partially purified extract components C1D5E8 of CV, C1D5E7, C1D5E4 and C1D5EX have showed activity.Freeze-dried component C1D5E8, C1D5E7, C1D5E4 and C1D5EX are weighed as 5,14,49 and 13mg respectively.Component C1D5E8, C1D5E7, C1D5E4 and C1D5EX are carried out in addition those steps of purification step, particularly decationize molecule.Embodiment XV in CV peptide connection dextran as the effect of the peptide component of antigenic determinant
This embodiment is relevant with the composition (neutral sugar, uronic acid and proteins/peptides) of the CV component basic structural unit with external mitogenic activity.Figure 16 has shown the relation between the content of basic structural unit of the stimulation index of external mitogenic response and each component.For the CV component of analyzing, peptide content and mitogenic activity closely related (r=0.99, p＜0.05).Relation conefficient between mitogenic activity and the glucuronic acid content is at 10% level significantly (r=0.61) hardly, and is not remarkable with the relation of neutral sugar.The external immunocompetence of the described assessment of EXAMPLE III as mentioned.The physical chemistry and the biological property of embodiment XVICV partial purification component
Determine molecular weight ranges and the molecular-weight average (referring to Table A) of component C1D5E8, C1D5E7 and C1D5EX.
Table A
The molecular weight ranges of C1D5E8, C1D5E7 and C1D5EX
Component Initial (kDa)
????C1D5E8 0.7-2.6; On average=0.8
????C1D5E7 1.6-52; On average=2.6
????C1D5EX (0.8-111 the peak seriously trails); On average=6.2
Determine neutral sugar, uronic acid and Protein content among component C1D5E8, C1D5E7 and the C1D5EX (referring to table B).
Table B
The chemical constitution of C1D5E8, C 1D5E7 and C1D5EX
Component Carbohydrate content (% total mass) Glucuronic acid content (% total mass) Protein (% total mass)
????C1D5E8 ??18.77±1.20 ??1.32±0.15 ??5.04±0.21
????C1D5E7 ??33.72±1.48 ??5.23±4.28 ??12.01±0.24
????C1D5EX ??75.86±6.82 ??16.95±0.92 ??8.76±0.31
As described in example II, determine neutral sugar, uronic acid and Protein content for component C1D5E8, C1D5E7 and C1D5EX.Analyze according to GC/MS, glucose is unique detectable monose.Glucose molecule connects by 1 → 3 key.
The aminoacid sequence of determining the proteins/peptides composition of component C1D5E7 is Asp-Cys-Pro-Pro-Cys-Glu (SEQ ID NO:1).Utilize Protein Sequencer (the Hewlett Packard 1000A protein sequencer of HPLC system is housed) to determine SEQ ID NO:1.
Determine the immunocompetence (referring to Figure 15) of the partially purified component C1D5E8 of CV, C1D5E7 and C1D5EX.Figure 17 shows that three partially purified active CV components are that C1D5E8, C1D5E7 and C1D5EX secrete nitric oxide production stimulating activity to the mouse peritoneal macrophages.Find that partially purified component of all CV and LPS have same activity and effectiveness (referring to Figure 17).The molecular weight of embodiment XVIICV crude extract and the partially purified extract of CV is to the influence of intestines permeability
Determine the intestines permeability of CV crude extract and the partially purified extract components C1D5E8 of CV, C1D5E7 and C1D5EX in the external Caco-2 of utilization cell monolayer Transwell method.The molecular weight distribution of the compound of more natural CV sample and permeable Caco-2 cell thereof.The HPLC system of utilization and Supedex 75 10/30 column couplings analyzes.Elution buffer is 200mM sodium chloride solution, pH7.0, and elutriant is monitored at the UV210nm place.
All experiments are carried out 37 ℃ the time under the temperature control condition.The transport buffer of the phosphate-buffered salt (PBS) of 80mM magnesium chloride and 90mM calcium chloride as all permeabilities measurements will be mixed with.Before the experiment, use twice of transport buffer washed cell individual layer.The transport buffer that 1.5ml is contained testing sample joins the substrate outside of Caco-2 cell monolayer.37 ℃ of balances were transferred to sample solution on the flat board of the cluster of using the filling of 2.6ml transport buffer earlier with Transwell after 30 minutes.When experiment finishes, collect the composition that sees through cell in the substrate outside.Sample desalination and freeze-drying with collecting are used for subsequently chemistry and biological assay.1.CV crude extract
Table C shows the CV crude extract composition (kDa) that can see through the Caco-2 cell monolayer below.
Figure 18 A is the size exclusion chromatography spectrum of CV crude extract, and the content of the permeable Caco-2 cell of collecting the back of CV crude extract is studied in Figure 18 B explanation in transhipment.By the CV crude extract of example I preparation, molecular weight ranges is 0.5-40kDa, average out to 2.6kDa.Shown in Figure 18 B, 7.07 and the peak of 8.89ml place wash-out be present in each sample (comprise contrast, promptly do not contain the CV crude extract) of collecting in the basal compartment.This result shows that the peak is not born for CV crude extract sample, but may be because the macromole that eats away from the Caco-2 cell.17.67ml the peak of wash-out is seemingly because the small molecules that exists in the CV crude extract in the component, rather than the biological activity dextran.According to the molecule spirogram shown in Figure 18 A and the 18B, we reach a conclusion, and low molecular weight compositions is than the easier leap individual layer of high molecular weight components.In addition, we also draw conclusion, and 3kDa may be the molecular weight upper limit of intestinal absorption CV crude extract.
Table C
The molecular weight ranges of C1D5E8, C1D5E7 and C1D5EX
The composition of permeable Caco-2 cell monolayer (kDa)
The CV crude extract 0.3-5 (but mainly between 0.3-3) on average=0.7
2.CV partially purified extract C 1D5E8, C1D5E7 and C1D5EX
Table D shows component C1D5E8, the C1D5E7 of permeable Caco-2 cell monolayer and the composition (kDa) of C1D5EX below.
Figure 19 A is the size exclusion chromatography spectrum that can permeate the material of Caco-2 cell among the C1D5E8.The molecular-weight average of C1D5E8 is 0.8kDa.Shown in Figure 19 B, the main amount of peptide connection dextran is eluted in the 16.73ml component, shows that the composition transhipment of the about 0.7kDa that exists in C1D5E8 strides across the individual layer of external absorption model.
Figure 20 A is the size exclusion chromatography spectrum of the material of permeable Caco-2 cell in C1D5E7.The molecular-weight average that C1D5E7 has is 2.6kDa (referring to Figure 20 A).When transhipment research finishes, have only more low-molecular-weight composition can detect (being that molecular-weight average is 1.2kDa) (referring to Figure 20 B) in the base side of Caco-2 cell monolayer.
Figure 21 A is the size exclusion chromatography spectrum of the material of permeable Caco-2 cell among the C1D5EX.The molecular-weight average of C1D5EX estimates to be about 6kDa (referring to Figure 21 A).Figure 21 B shows that except the small molecular weight of 17.67ml place wash-out very small amount of other compositions also are penetrated into the substrate outside of individual layer by the intestines barrier.
Table D
The molecular weight ranges of C1D5E8, C1D5E7 and C1D5EX
Component To the permeable composition of Caco-2 cell monolayer (kDa)
????C1D5E8 0.3-2; On average=0.7
????C1D5E7 (0.3-5 but mainly between 0.3-3); On average=1.2
????C1D5EX Detect inapparent amount
Embodiment XVIII and the external mouse macrophage that contacts of the composition of the permeable Caco-2 cell of the partially purified extract of CV
Figure 22 illustrates that the mouse peritoneal macrophages that contacts with the composition of the permeable Caco-2 cell of CV partial purification extract or LPS is to the external influence of nitrogen protoxide excretory.The composition of the permeable cell of the partially purified sample of all CV is immunocompetent, and all samples has bigger activity than LPS.Lower molecular weight component and intermediate molecular weight component C1D5E8, C1D5E7 show stronger activity than high molecular weight component C1D5EX more respectively.The molecular-weight average that peptide connection dextran in C1D5E8 and C1D5E7 has is less than about 3kDa.Embodiment XIX is to the partially purified extract research and design of normal mouse administration CV
25 ICR mouse are divided into 5 groups, every group each 5.As shown in Table VIII, each group of following processing.The administration of the partially purified extract C 1D5E8 intraperitoneal of group 1 usefulness CV is handled; The administration of the partially purified extract C 1D5E7 intraperitoneal of group 2 usefulness CV is handled; The administration of the partially purified extract C 1D5E4 intraperitoneal of group 3 usefulness CV is handled; The administration of the partially purified extract C 1D5EX intraperitoneal of group 4 usefulness CV is handled; Administration is handled with the common salt solution intraperitoneal of group 5 usefulness, as negative control.
Table VIII shows the dosage of each group and the plan of taking medicine.Mouse at the 8th day execution group 1-5.
Preparation and storage CV crude extract, example VI is described as mentioned, is used for intraperitoneal or oral administration.
Table VIII
Treatment group The mouse number Endoxan dosage and the plan of taking medicine CV dosage and the plan of taking medicine Route of administration
????1 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) C1D5E8 5-7 days, 50mg/kg/ days (the 5mg/ml injection of solution of 0.25ml is gone in the mouse of about 25g) Intraperitoneal
????2 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) C1D5E7 5-7 days, 50mg/kg/ days (the 5mg/ml injection of solution of 0.25ml is gone in the mouse of about 25g) Intraperitoneal
????3 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in the mouse of about 25g) C1D5E4 5-7 days, 50mg/kg/ days (the 5mg/ml injection of solution of 0.25ml is gone in the mouse of about 25g) Intraperitoneal
????4 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone in about 25g mouse) C1D5EX 5-7 days, 50mg/kg/ days (the 5mg/ml injection of solution of 0.25ml is gone in the mouse of about 25g) Intraperitoneal
????5 ????5 The 1st day, 20mg/kg/ days (the 1mg/ml injection of solution of 0.5ml is gone into the mouse of about 25g) 5-7 days, the aseptic ordinary salt aqueous solution of 0.25ml pH7.4 Intraperitoneal
1. the partially purified extract of intraperitoneal administration CV is to the influence from the mice spleen cell proliferation in vivo alive of normal mouse
When with control mice (group 5) relatively the time, the number of the splenocyte of living in all groups (group 1-4) (p＜0.001) display body increases (referring to Figure 23 A).Among the group 1-3, C1D5E8, C1D5E7 and C1D5E4 show that respectively spleens cell number has improved about 100%.In the group 4, C1D5EX (the partially purified extract of the CV of highest weight) shows that spleens cell number improves about 64%.
As results and separating Morr. cell as described in the EXAMPLE III.Preparation cell suspending liquid, and the viability of the described test cell suspension of EXAMPLE III as mentioned.2. the partially purified extract of intraperitoneal administration CV is to the influence from the medullary cell proliferation in vivo alive of normal mouse
All groups (group 1-4) have shown when with control group (group 5) relatively the time, the bone marrow cell increase (referring to Figure 23 B) of living in the body.Have only the C1D5EX in the group 4 to show the significantly increase (p＜0.002) statistically of efficient bone marrow cell.
As results as described in the EXAMPLE IV with separate medullary cell.Preparation cell suspending liquid, and the viability of the described test cell suspension of EXAMPLE III as mentioned.Embodiment XX is to the general material of the partially purified extract of mouse administration CV and the method for non-responsiveness
25 ICR mouse are divided into 5 groups, every group each 5.As shown in Table IX, each group of following processing.The mouse of the described immunosuppression group of example VII A 1-5 as mentioned.The partially purified extract C 1D5E8 oral administration of group 1 usefulness CV is handled; The partially purified extract C 1D5E7 oral administration of group 2 usefulness CV is handled; The partially purified extract C 1D5E4 oral administration of group 3 usefulness CV is handled; The partially purified extract C 1D5EX oral administration of group 4 usefulness CV is handled; Handle with group 5 usefulness deionized water oral administrations, as negative control.Table I X shows the dosage of each group and the plan of taking medicine.The mouse of group 1-5 was put to death at the 8th day.
As preparation and administration endoxan as described in the example VII A.Example VI is described as mentioned, and preparation and storage CV crude extract are used for intraperitoneal or oral administration.
Table I X
Treatment group The mouse number Partially purified fragment of CV and dosage The CV plan of taking medicine Route of administration
????1 ????5 C1D5E8 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) 1-7 days Oral
????2 ????5 C1D5E7 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) 1-7 days Oral
????3 ????5 C1D5E4 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) 1-7 days Oral
????4 ????5 C1D5EX 50mg/kg/ days (the oral mouse that feeds about 25g of the 5mg/ml solution of 0.25ml) 1-7 days Oral
????5 ????5 0.25ml deionized water 1-7 days Oral
1. the partially purified extract of oral administration CV is to the influence from the mice spleen cell proliferation in vivo alive of the mouse of non-responsiveness
When with control mice (group 5) comparison, the partially purified extract of mouse oral administration CV of group 1-4 has been improved the number (referring to Figure 24 A) of the splenocyte of living in the body.When with control mice (group 5) comparison, to organizing the number (having increased by 66%) that 1 administration C1D5E8 has significantly improved the splenocyte of living in (p＜0.01) body.When with control mice (group 5) comparison, to organizing the number that 2 administration C1D5E7 have significantly improved the splenocyte of living in (p＜0.01) body.When with control mice (group 5) comparison, to organizing the number that 3 administration C1D5E4 have significantly improved splenocyte in (p＜0.05) body.When with control mice (group 5) comparison, there is not significantly to increase the number of splenocyte alive in the body to organizing 4 administration C1D5EX.
As results and separating Morr. cell as described in the EXAMPLE III.The preparation cell suspending liquid, and as the viability of test cell suspension as described in the EXAMPLE III.2. the partially purified extract of oral administration CV is to the influence from the intravital propagation of medullary cell alive of the mouse of non-responsiveness
All groups (group 1-4) have shown when with control mice (group 5) relatively the time, the number increase (referring to Figure 24 B) of the medullary cell of living in the body.
When with control mice (group 5) comparison, significantly increased the number of the medullary cell of living in (p＜0.001) body to organizing 1 administration C1D5E8.When with control mice (group 5) relatively the time, to organize 2, group 3 and organize 4 administration C1D5E7, C1D5E4, C1D5EX have significantly increased the number of (p＜0.05) intravital medullary cell alive respectively.
As results as described in the EXAMPLE IV with separate medullary cell.Preparation cell suspending liquid, and the viability of the described test cell suspension of EXAMPLE III as mentioned.1. species are kept
The mouse (inbred lines) of ICR (ICR) is provided by the Animal House of Hong Kong Chinese University.The mouse that each cage is raised is less than 20.In maintaining the equipment of about 40-70%, 18-26 ℃, relative humidity raise mouse in temperature maintenance.Light/dark circulation maintains 12 hours interval.Feed mouse with rodent food dietary standards.The mouse weight that is used for the foregoing description is at 25-30g, and is 8-12 age in week.2.Caco cell culture
With the Caco-2 cell (available from American type culture collection, Rockwille, Md.) be supplemented with 25mM D-glucose, (all reagent are from Gibbs BRL to contain the DMEM substratum of 10%FBS, 1% indispensable amino acid, 1%L-glutamine, 1mM Sodium.alpha.-ketopropionate, penicillin (100U/ml) and Streptomycin sulphate (100 μ g/ml), Life Technologies, Inc., Gaithersburg, Md.) in, 37 ℃, 5%CO 2And 90%O 2Atmosphere is growth and daily keeping down.When about 70% converges, with 0.05% trypsinase-EDTA harvested cell, and with cell density 3 * 10 5Cell/filter is seeded on the polycarbonate filter, and it is earlier with type i collagen albumen bag quilt (3.0 μ m holes, 4.71cm 2Growth district), be positioned at the Transwell cell cultures indoor (available from Costar-Coming, Rockwille, MD).Per 48 hours replacement mediums (inserting in the body (insert) 1.5ml and 2.6ml in the cluster flat board) at Transwell.The inoculation back utilized individual layer in the time of the 21st to 25 day.3. damping fluid dissolves damping fluid
8.29g?NH 4Cl
1.002g?NaHCO 3
29.2mg?EDTA
All reagent all are dissolved in the 1L deionized water, pH regulator to 7.2, and by 0.22 μ m sterile filters filtration sterilization.4. complete cell culture medium
The Streptomycin sulphate of v/v tire ox salt solution (FBS), 100IU/ml penicillin and 100 μ g/ml with 10% mixes in RMPI 1640 substratum (Gibco).
Publication and patent application that all are quoted as proof above are incorporated herein by reference in full, and be all identical for all purposes, and it is all specific and be incorporated herein by reference individually to resemble single publication or patent application.Though for clear and understand purpose, be described in detail by explanation and embodiment the present invention, obviously within the scope of the appended claims, some variation and modification can be carried out.Unless from context, can understand utilization in addition otherwise the element of the invention described in the application's book, step, feature and embodiment can mutually combine.
Reference
1.Parslow the T.G. immunne response, Medical Immunology (Medical Immunology); Stites D.P., Terr A.I., Parslow T.G. compiles, Appleton and Lange:London, 1997; The 63-73 page or leaf.
2.Tsukagoshi S.Krestin (PSK). cancer therapy summary (Cancer treatmentreview) 1984,11,131-155 page or leaf.
3.Descotes the immunity analysis that J. is cell-mediated, immunotoxicity are crossed the threshold (AnIntroduction to Immunotoxicity); Taylor ﹠amp; Francis Ltd; London, 1999; The 103-110 page or leaf.
4.Descotes the immunosuppressant assessment strategy of J., immunotoxicity are crossed the threshold (AnIntroduction to Immunotoxicity); Taylor ﹠amp; Francis Ltd; London, 1999; The 125-136 page or leaf.
5.Lennernas the permeability of H. people's intestines, J.Pharm.Sci., 1998,87 (4), 403-410 page or leaf.
6.Borchardt R.T., Hidalgo I.J., Hillgren K.M., the medicinal application of Hu M. cell culture: summary, Pharmaceutical Applications of Cell and TisssueCulture to Drug Transport; Wilson G. compiles; Plenum press:New York, 1991; The 1-14 page or leaf.
7.Lee V.H.L. peptide and proteinic medicine are sent, Trends and FuturePerspectives, Peptide and Protein Drug Dilivery; Lee V.H.L., Hashida M., Mizushima Y. compiles; Harvard academic press: London, 1995; The 3-15 page or leaf.
8.Ueno S., Yoshikumi C., Omura Y., Fujii T., Wada T., TakahashiE., Hirose F. United States Patent (USP) 4,699,787; Nitrogenous polysaccharide, on November 13rd, 1987.
9.Ueno S., Yoshikumi C., Omura Y., Fujii T., Wada T., TakahashiE., Hirose F. United States Patent (USP) 4,851,395: nitrogenous polysaccharide, on July 25th, 1989.
10.Ikuzawa M., Oguchi Y., Matsunaga K., Toyoda N., Furusho T., Fujii T., Yoshikumi C. United States Patent (USP) 4,820,689: contain the pharmaceutical composition of glycoprotein, on April 11st, 1989.
11.Ikuzawa M., Oguchi Y., Matsunaga K., Toyoda N., Furushe T., Fujii T., Yoshikumi C. United States Patent (USP) 5,008,243: contain the pharmaceutical composition of glycoprotein, on April 6th, 1991.
12.Suguira M., Ohno H., Sasaki Y., Hama K. United States Patent (USP) 4,225,673: have the dextran of anti-tumor activity, on September 30th, 1980.
13.Yang M.P., Chen G. United States Patent (USP) 5,824,648:Rnase-CV (rainbow conk), on October 20th, 1998.
14.Yang M.P., Chen G. United States Patent (USP) 6,087,335:Rnase-CV (rainbow conk), on July 11st, 2000.
Sequence table＜110〉Hong Kong Chinese University (THE CHINESE UNIVERSTITY OF HONG KONG)＜120〉preparation and calibrating have the immunoregulatory peptide connection dextran of verifiable oral absorption rainbow conk
(PREPARATION?AND?STANDARDIZATION?OF?IMMUNOMODULATORY?PEPTIDE-LINKED
GLUCANS WITH VERIFIABLE ORAL ABSORBABILITY FROM CORIOLUS VERSICOLOR)＜130〉SPI031063-47＜150〉USP 60/383,339＜151〉2002-05-22＜150〉USP 10/236,996＜151〉2002-09-06＜160〉1＜170〉PatentIn version 3.1＜210〉1＜211〉6＜212〉PRT＜213〉unknown＜220〉＜albumen/peptide component＜400 among 223〉the Coriolus Versicolor P.E. component C1D5E7〉1Asp Cys Pro Pro Cys Glu 6

Claims (58)

1. the extract of the purifying of a rainbow conk, it comprises at least a peptide connection dextran that contains the glucose molecule that connects by (1 → 3) key, has the 0.3kDa that determined by the size exclusion chromatography molecular weight to 5kDa, and has immunostimulatory activity.
2. the extract of the described purifying of claim 1, wherein molecular weight is 0.7kDa.
3. the extract of the described purifying of claim 1, wherein molecular-weight average is 2.6kDa.
4. the extract of the described purifying of claim 2, wherein peptide connection dextran can be carried out the intestinal absorption determined by Caco-2 cell monolayer Transwell method.
5. the extract of the described purifying of claim 3, wherein peptide connection dextran can be carried out the intestinal absorption determined by Caco-2 cell monolayer Transwell method.
6. the extract of the described purifying of claim 1, its preparation process is as follows:
Use alkaline purification rainbow conk, and separation of supernatant;
Supernatant liquor is carried out cationic exchange;
To carry out anionresin from the eluate of cationic exchange;
To separate by the size fractionation isolation technique from the eluate of anionresin, and collect the component that contains at least a peptide connection dextran.
7. the extract of the described purifying of claim 6, wherein the size fractionation isolation technique is that molecule is got rid of chromatography or alcohol grading separates.
8. the extract of the described purifying of claim 6, wherein cationic exchange is carried out on the CM cellulose column.
9. the extract of the described purifying of claim 6, wherein anionresin is carried out on the DEAE cellulose column.
10. the extract of the described purifying of claim 1, wherein peptide connection dextran water soluble, ethanol and acetone are insoluble to chloroform and two chloroforms, and are non-moisture absorptions.
11. the isolating peptide connection dextran of a rainbow conk, it comprises a plurality of glucose molecules that connect by (1 → 3) key, and molecular weight is defined as 0.7kDa to 3.0kDa by size exclusion chromatography; And isolating peptide joins dextran and activeconstituents has immunostimulatory activity.
12. the described activeconstituents of claim 11, it is the peptide component of peptide connection dextran.
13. the described activeconstituents of claim 11, it is the dextran composition of peptide connection dextran.
14. the extract of the purifying of claim 1, wherein peptide connection dextran can be carried out by the definite intestinal absorption of Caeo-2 cell monolayer Transwell method.
15. the described a plurality of peptide connection dextran of claim 11, wherein molecular-weight average is 0.8kDa.
16. the described peptide connection of claim 11 dextran, wherein molecular weight is 0.7kDa.
17. the described a plurality of peptide connection dextran of claim 11, wherein molecular-weight average is 2.6kDa.
18. the described a plurality of peptide connection dextran of claim 11, wherein molecular-weight average is 6.2kDa.
19. the described a plurality of peptide connection dextran of claim 11, wherein molecular-weight average is less than 3.0kDa.
20. the described peptide connection of claim 11 dextran, wherein peptide connection dextran can be carried out by the definite intestinal absorption of Caco-2 cell monolayer Transwell method.
21. the described activeconstituents of claim 12, wherein activeconstituents can carry out by the definite intestinal absorption of Caco-2 cell monolayer Transwell method.
22. the described activeconstituents of claim 13, wherein activeconstituents can carry out by the definite intestinal absorption of Caco-2 cell monolayer Transwell method.
23. the described peptide connection of claim 11 dextran, its preparation process is as follows:
Use alkaline purification rainbow conk, and separation of supernatant;
Supernatant liquor is carried out cationic exchange;
To carry out anionresin from the eluate of cationic exchange; With
To separate by the size fractionation isolation technique from the eluate of anionresin and collect and contain the component that a kind of peptide joins dextran.
24. the described peptide connection of claim 23 dextran, wherein the size fractionation isolation technique is that molecule is got rid of chromatography or alcohol grading gradient.
25. the described peptide connection of claim 23 dextran, wherein cationic exchange is carried out on the CM cellulose column.
26. a pharmaceutical composition, it contains each described extract of aforementioned claim or isolating peptide connection dextran.
27. the method for a purified peptide connection dextran, it comprises the steps:
Use alkaline purification rainbow conk, and separation of supernatant;
Supernatant liquor is carried out cationic exchange;
To carry out anionresin from the eluate of cationic exchange; With
To separate by the size fractionation isolation technique from the eluate of anionresin, and collection contains peptide connection dextran, molecular weight is the component of 0.7-5kDa.
28. the described method of claim 27, wherein treatment step comprises:
Macerate the sporocarp of rainbow conk;
The rainbow conk sporocarp of macerating with alkaline extraction is to obtain extract;
From extract, remove insoluble substance;
Clarify the supernatant liquor of first extract; With
Concentrated supernatant obtains the 3rd extract, wherein the 3rd crude extract is carried out cationic exchange.
29. the described method of claim 28, wherein the alkaline extraction step comprises the rainbow conk sporocarp of macerating is boiled in alkaline aqueous solution.
30. the described method of claim 29, wherein alkaline aqueous solution is selected from sodium hydroxide and potassium hydroxide.
31. the described method of claim 29, wherein the equivalent concentration of alkaline aqueous solution is less than or equal to 0.1N.
32. the described method of claim 29, wherein the equivalent concentration of alkaline aqueous solution is 0.01N.
33. the described method of claim 27, wherein insoluble substance is removed from first extract by filtering.
34. the described method of claim 29, the component that wherein contains peptide connection dextran, molecular weight and be 0.7-5kDa is by centrifugal clarification.
35. the described method of claim 29, the component that wherein contains peptide connection dextran, molecular weight and be 0.7-5kDa are by rotary evaporation, freezing or freeze-drying is spissated.
36. the described method of claim 27, the molecular weight that wherein contains the component of peptide connection dextran is that 0.7kDa arrives about 3.0kDa.
37. the method that immune stimulatory is replied, it comprises immune cell and claim 1,6 or 11 each described extracts, peptide connection dextran or its activeconstituents is contacted.
38. the described method of claim 37, wherein cell is splenocyte or medullary cell, and the proliferative response of contact trigger cell.
39. the described method of claim 37, wherein cell is a scavenger cell, and contact trigger cell secretion nitrogen protoxide.
40. the described method of claim 37, wherein contact takes place in vivo.
41. the described method of claim 37, wherein contact is ectogenetic.
42. a treatment needs the patient's of immunity system stimulation method, it comprises peptide connection dextran or its activeconstituents to the claim 1 of patient's effective dosage, 6,11 or 23 described extracts, purifying, replys with immune stimulatory.
43. the described method of claim 42, wherein the patient is an immune deficiency.
44. the described method of claim 42, wherein the patient is asymptomatic but is subject to the immune deficiency influence.
45. the described method of claim 42, wherein immune deficiency is the result of infection, malignancy disease, autoimmune disease, protein loss state, immunosuppressant therapy, surgical operation or anesthesia.
46. the described method of claim 45 wherein infects being selected from rubella, congenital rubella, measles, leprosy, tuberculosis, coccidioidomycosis, chronic infection, acute viral infection, cytomegalovirus, multiple virus infection and virus infection repeatedly.
47. the described method of claim 45, wherein malignancy disease is selected from Hodgkin's disease, acute leukemia, chronic leukemia, non-lymphatic cancer and myelomatosis.
48. the described method of claim 45, wherein autoimmune disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis and chronic active hepatitis.
49. the described method of claim 45, wherein protein loss state is selected from nephrotic syndrome and protein loss property enteropathy.
50. the described method of claim 45, wherein immunosuppressant therapy is selected from reflunomide, cytotoxic drug, alkylating reagent, metabolic antagonist, antithymocyte globulin, radiation, S-Neoral, phenytoin and Trolovol.
51. the described method of claim 45, wherein immune deficiency is the result who is selected from down a kind of illness of group: diabetes, alcoholic liver cirrhosis, malnutrition, burn, sarcoidosis, splenectomy, sicklemia, uremia, aging, subacute sclerosing panencephalitis, mongolism, newborn infant and premature infant.
52. the described method of claim 42, wherein immunne response comprises the propagation of splenocyte or medullary cell, or scavenger cell secretion nitrogen protoxide.
53. the described method of claim 42, it comprises that further the symptom of monitoring the patient is to detect improvement or the prevention to the symptom of dosing step reaction.
54. the described method of claim 42, wherein immune deficiency is patient's a acquired immunodeficiency.
55. the described method of claim 54, wherein acquired immunodeficiency is the result that human immunodeficiency virus (HIV) infects.
56. the described method of claim 55, wherein the patient is just suffering from or is being subject to be selected from down the influence of the disorder of group: 1 type simplexvirus, type 2 herpesvirus, cytomegalovirus, varicella, adenovirus (adenovirus), Epstein-Barr virus, HTLV-1, HTLV-III, white candiyeast (Candida albicans), novel Cryptococcus (Cryptococcus neoformans), Nocardia bacteria kind (Nocardia sps.), Pneumocystis carinii, toxoplasma gondii (Toxoplasmagondii), Isospora sp, Cyptosporidium, Giardia lamblia, Entamoebahistolytica, Mycobacterium tuberculosis (Mycobacterium tuberculosis), bird mycobacterium (Mycobacterium avium-intracellulare) in the cell, mycobacterium kansasii (Mycobacterium kansasii), legionella (Legionella sp), treponema (Treponema sp), Treponoma palladium (Treponema pallidum), the crooked Helicobacter pylori (Campylobacter sp) of saliva, Neisseria gonorrhoeae (Neisseria sp), Diplococcus gonorrhoeae (Neisseria gonorrhoeae), Shigellae (Shigella), Salmonellas (Salmonella sp) and chlamydozoan (Chlamydia).
57. the described method of claim 42, its further comprise monitoring among the patient splenocyte and/or the propagation of medullary cell to detect immunostimulation to the dosing step reaction.
58. the described peptide connection of claim 11 dextran, its feature is that also aminoacid sequence is SEQ ID NO:1.
CNB031410073A 2002-05-22 2003-05-22 Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk Expired - Lifetime CN100471869C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38333902P 2002-05-22 2002-05-22
US60/383,339 2002-05-22
US10/236,996 2002-09-06

Publications (2)

Publication Number Publication Date
CN1459459A true CN1459459A (en) 2003-12-03
CN100471869C CN100471869C (en) 2009-03-25

Family

ID=29550186

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB031410073A Expired - Lifetime CN100471869C (en) 2002-05-22 2003-05-22 Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk

Country Status (1)

Country Link
CN (1) CN100471869C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103070010A (en) * 2012-12-27 2013-05-01 陕西恒田化工有限公司 Coriolus versicolor strain and method for extracting Coriolus versicolor glucan by utilizing fermentation products of Coriolus versicolor strain
EP2627341A2 (en) * 2010-10-06 2013-08-21 Purapharm Company Limited Coriolus versicolor extracts, methods of preparation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627341A2 (en) * 2010-10-06 2013-08-21 Purapharm Company Limited Coriolus versicolor extracts, methods of preparation and uses thereof
CN103298476A (en) * 2010-10-06 2013-09-11 培力有限公司 Coriolus versicolor extracts, methods of preparation and uses thereof
EP2627341A4 (en) * 2010-10-06 2014-04-02 Purapharm Company Ltd Coriolus versicolor extracts, methods of preparation and uses thereof
US10226493B2 (en) 2010-10-06 2019-03-12 Bagi Research Limited Coriolus versicolor extracts, methods of preparation and uses thereof
CN103070010A (en) * 2012-12-27 2013-05-01 陕西恒田化工有限公司 Coriolus versicolor strain and method for extracting Coriolus versicolor glucan by utilizing fermentation products of Coriolus versicolor strain

Also Published As

Publication number Publication date
CN100471869C (en) 2009-03-25

Similar Documents

Publication Publication Date Title
Zhang et al. Toxicology and immunology of Ganoderma lucidum polysaccharides in Kunming mice and Wistar rats
CN1505524A (en) Immunopotentiators
CN1427725A (en) Casein derived peptides and uses thereof in therapy
CN1285752A (en) Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
Meng et al. Water-soluble polysaccharides from Grifola Frondosa fruiting bodies protect against immunosuppression in cyclophosphamide-induced mice via JAK2/STAT3/SOCS signal transduction pathways
CN1192098C (en) Bio-active substance of antrodia camphorata mycelia, its preparing process and its composition
US8158750B2 (en) Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
CN1198639C (en) Immune enhancing compositions
CN1557842A (en) Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof
CN1459459A (en) Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk
CN1831015A (en) Process for extracting fructus ligustri lucidi and Radixa stragali polysaccharide, the products and application thereof
An et al. Effect of Chlorella vulgaris on immune-enhancement and cytokine production in vivo and in vitro
Wu et al. Bioactive ingredients and medicinal values of Grifola frondosa (Maitake). Foods 2021; 10: 95
CN114230646B (en) Antitumor grifola frondosa glycoprotein and preparation method and application thereof
CN1652805A (en) An herbal composition for the treatment and remedy of bronchial respiratory difficulties
CN1452973A (en) Orally taken antioxidant and antilipemic medicine
CN1767837A (en) Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 for immune activation or prevention and treatment of cancer and the preparation method thereof
CN1566136A (en) Pasqueflower notoginsenosides and extraction method, medicinal uses and pharmaceutical preparation thereof
CN1171630C (en) LAK activity potentiator orginating in shiitake mushroom hyphae extract and LAK activty potentiating preparations containing the same
CN100345538C (en) Use of ampelopsin for preparing blood sugar reducing medicine
CN1546533A (en) Hericium erinaceus sulfate proteoglycan, preparation method thereof and pharmaceutical compositions with the same as active component
CN1088826A (en) A kind of medicine for the treatment of primary glomerulopathy and chyluria and preparation method thereof
Ryu et al. Effect of Salicornia herbacea polysaccharides on the activation of immune cells in vitro and in vivo
US20240058410A1 (en) Method for preparing a feeding instant astragalus polysaccharide powder and application thereof
CN1629186A (en) Ganoderma lucidum polysaccharide protein and its preparing method and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059088

Country of ref document: HK

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1059088

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20090325

CX01 Expiry of patent term